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Chapter I 
Wnt/β-catenin Signaling in Adipogenesis and Metabolism 
 
Summary 
 Adipocyte differentiation consists of a complex series of events in which 
scores of cellular and extracellular factors interact to transform a fibroblast-like 
preadipocyte into a mature, lipid-filled adipocyte.  Many of the pathways 
influencing this process have been identified using well-characterized 
preadipocyte culture systems and have subsequently been confirmed in animal 
models.  Research conducted over the last decade has established the Wnt/β-
catenin signaling pathway as an important regulator of adipocyte differentiation.  
While initial reports implicated activators of Wnt/β-catenin signaling as potent 
inhibitors of adipogenesis, recent investigations of mesenchymal cell fate, 
obesity, and type 2 diabetes highlight significant additional roles for Wnt signaling 
in metabolism and adipocyte biology. 
 
Introduction 
 Adipogenesis is the process by which mesenchymal precursor cells 
differentiate into adipocytes, which store lipid and serve as central regulators of 
metabolism [1-3].  Identifying key factors that control adipocyte differentiation and 
metabolism is vital to understanding adipose tissue biology and pathology.  The 
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transcriptional cascade controlling adipogenesis has been well characterized 
over the past two decades and mechanisms by which master adipocyte 
regulators act are now beginning to be fully elucidated.  Peroxisome proliferator-
activated receptor γ (PPARγ) and CCAAT/enhancer binding protein α (C/EBPα) 
are the chief regulators thought to coordinately direct the adipogenic program.  
PPARγ is both necessary and sufficient for preadipocyte differentiation [1], while 
C/EBPα appears to be important for the acquisition of insulin sensitivity in 
adipocytes [4].  The current state of research on these important transcriptional 
regulators has been recently reviewed elsewhere [2,3].   
 Transcription factors that control the cascade of events leading to a fully 
differentiated adipocyte act downstream of complex signaling pathways that 
integrate signals from the surrounding microenvironment.  Over the past several 
years, the field of adipogenesis has seen an upsurge in the number of reports 
implicating locally secreted or circulating extracellular factors as regulators of 
preadipocyte differentiation [3].  One of the extracellular signaling pathways now 
known to affect adipogenesis is the Wnt pathway.  Wnts are an evolutionarily 
conserved family of secreted lipidated glycoproteins with well-established roles in 
cellular proliferation, differentiation, and polarity during embryogenesis [5,6].  
More recently, Wnt signaling has been shown to modulate additional 
developmental and physiological processes, including aspects of adipocyte 
biology [7-11].  In this review, we provide an overview of the research revealing a 
principal role for Wnt signaling in adipogenesis.  We present a brief chronology of 
the studies demonstrating Wnt inhibition of adipocyte differentiation in vitro and in 
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vivo, culminating with the recent linkages of Wnt pathway members to human 
diseases including obesity and type 2 diabetes.  Finally, we examine the latest 
reports providing mechanistic insight into how Wnt signaling functions to block 
adipogenesis and regulate mesenchymal cell fate. 
 
Wnt Signaling Regulates Adipogenesis In Vitro and In Vivo: 
 Wnts are secreted proteins that act though autocrine and paracrine 
mechanisms to influence the development of many cell types [5,6].  Although 
Wnts can inhibit preadipocyte differentiation through both β-catenin-dependent 
and -independent mechanisms [12], current genetic evidence supports β-catenin 
as a particularly crucial regulator of adipogenesis [13].  In the canonical Wnt 
signaling pathway, β-catenin plays a central role as a transcriptional coactivator.  
Upon binding of Wnt ligands to frizzled receptors and low density lipoprotein 
receptor-related protein (LRP) coreceptors, cytoplasmic β-catenin is 
hypophosphorylated, stabilized, and translocated into the nucleus where it binds 
to and coactivates members of the T-cell factor/lymphoid-enhancing factor 




 Studies utilizing preadipocyte lines originally demonstrated that ectopic 
expression of Wnt1, an activator of Wnt/β-catenin signaling, potently represses 
adipogenesis (Fig. 1.1) [7,11].  Similarly, pharmacological agents that activate 
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canonical Wnt signaling and stabilize free cytosolic β-catenin also block 
preadipocyte differentiation [7,8].  Conversely, inhibition of Wnt signaling in 
preadipocytes stimulates differentiation [7,8,14-16], suggesting that 
preadipocytes produce endogenous Wnts that strongly repress adipogenesis.  
One endogenous factor is Wnt10b, expression of which is high in dividing and 
confluent preadipocytes and is rapidly downregulated in response to elevated 
cAMP during induction of differentiation [7,8].  Furthermore, constitutive 
expression of Wnt10b stabilizes free cytosolic β-catenin and inhibits 
adipogenesis (Fig. 1.1) [7].  While considerable evidence suggests that Wnt10b 
is a prominent extracellular regulator of adipogenesis, other Wnt ligands are also 
expressed and likely contribute to the process.  For example, Wnt6 and Wnt10a 
have been identified as endogenous regulators of brown adipocyte development 
[17,18].  Additionally, Wnt5b is transiently induced during adipogenesis and acts 
through an unknown mechanism to destabilize β-catenin and promote 
differentiation [19,20], indicating that preadipocytes integrate inputs from a 
variety of competing Wnt signals (Fig. 1.1).  One of the mechanisms by which 
Wnt/β-catenin signaling inhibits adipogenesis is thought to involve dysregulated 
expression of cyclin dependent kinase inhibitors, p21 and p27 [21]. 
Adipogenesis is regulated not only by expression of specific Wnt ligands, 
but also by expression of factors that inhibit the Wnt/β-catenin pathway.  For 
example, Li et al. recently reported that a nuclear β-catenin antagonist, chibby 
(Cby), is expressed in adipose tissue and is induced during differentiation of 3T3-
L1 preadipocytes (Fig. 1.1) [14].  Cby binds the C-terminal portion of β-catenin 
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and blocks interaction with TCF/LEF transcription factors, thus repressing β-
catenin-mediated transcriptional activation [22].  Ectopic expression of Cby in 
3T3-L1 cells induces spontaneous differentiation into mature adipocytes, while 
depletion of Cby stimulates β-catenin activity and blocks differentiation of both 
3T3-L1 preadipocytes and mouse embryonic stem cells [14]. In harmony with 
these findings, another inhibitor of Wnt/β-catenin signaling, Dickkopf-1, is 
transiently expressed during human adipogenesis, and promotes differentiation 
of 3T3-L1 cells (Fig. 1.1) [16].  
 
In Vivo 
 In accordance with its expression during adipogenesis in vitro, Wnt10b is 
highly expressed in stromal vascular cells, which are enriched for preadipocytes, 
but not in mature adipocytes. While there is no evidence that a deficiency of 
Wnt10b in mice alters adipose tissue development, overexpression of Wnt10b in 
adipose tissues causes a 50% reduction in adiposity under standard laboratory 
conditions [9], and these mice resist expansion of adipose tissue under 
conditions of diet-induced and genetic obesity [9,10].  Mice expressing the 
Wnt10b transgene also show improved glucose homeostasis and increased 
insulin sensitivity [9,10].  Interestingly, expression of Wnt10b either blocks brown 
adipose tissue development, or stimulates its conversion to white adipose tissue, 
depending upon promoter usage [9,23].  
Regulated expression of endogenous inhibitors of Wnt signaling may also 
be important for modulating Wnt activity in vivo.  For example, expression of 
  6 
secreted frizzled-related protein (SFRP) 2, a putative extracellular Wnt inhibitor, 
is elevated in visceral adipose tissue compared to subcutaneous depots [24].  
Two additional inhibitors of the Wnt pathway, SFRP5 and naked1, were recently 
found to be expressed in mature adipocytes and are positively correlated with 
increasing adiposity (Fig. 1.1) [25].  Furthermore, male mice deficient in SFRP1 
show a 22% decrease in percent body fat [26] while elevated levels of SFRP1 
are observed in individuals that display enhanced orbital adipogenesis 
associated with Graves’ ophthalmopathy [27].  More research is needed to 
determine mechanisms by which SFRPs function in adipose tissue biology as 
recent studies suggest that these factors may also have functions independent of 
Wnt inhibition [28-30].  
 
Wnt/β-catenin Signaling and Human Metabolic Disorders. 
 The importance of Wnt signaling in human health is illustrated by recent 
genetic research implicating members of the Wnt/β-catenin pathway in metabolic 
diseases.  For example, polymorphisms of the Wnt10b and LRP5 genes may be 
associated with obesity in populations of European origin [31,32] while a 
mutation in LRP6 has been correlated with early coronary disease and multiple 
metabolic risk factors, including hyperlipidemia [33].  Furthermore, Wnt5b and 
transcription factor 7-like 2 (TCF7L2; formerly TCF4) variants have been linked to 
type 2 diabetes in ethnically diverse populations [19,34].  Following the initial 
report in which Grant et al. identified a link between TCF7L2 polymorphisms and 
susceptibility to type 2 diabetes in Icelandic, Danish, and U.S. cohorts [34], a 
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number of studies were subsequently conducted that confirmed and extended 
this finding.  Cohorts analyzed in the U.K., Finland, France, and Sweden 
demonstrated that variation in the TCF7L2 genomic region does indeed affect the 
risk for developing type 2 diabetes in these populations [35-38].  Within the U.S., 
polymorphisms in TCF7L2 were found to be associated with type 2 diabetes in 
large cohorts of both men and women across different ethnic backgrounds [39-
41].  The mechanism by which the TCF7L2 gene is related to risk of type 2 
diabetes remains unknown.  However, because Wnt signals through TCF7L2 to 
activate glucagon-like peptide 1 [42], a putative mechanism in which altered 
levels of glucagon-like peptide 1 influence insulin secretion from pancreatic β-
cells has been proposed [34].  Indeed, the reduction of insulin secretion observed 
in individuals harboring these polymorphisms is consistent with this hypothesis 
[43].  Additional studies will be required to determine the precise role of altered 
Wnt signaling in the pathogenesis of type 2 diabetes and other metabolic 
disorders, and to establish whether primary defects in adipose tissue are 
involved. 
 
Recent Advances in Wnt/β-catenin-Mediated Effects on Adipogenesis 
Regulation of Mesenchymal Cell Fate 
 Current research is focused on delineating mechanisms by which Wnt 
signaling influences developmental and physiological processes, with 
considerable progress made on the role of Wnt signaling in mesenchymal stem 
cells.  Multipotent precursors of the mesenchymal lineage possess the ability to 
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differentiate into various cell types including osteoblasts and adipocytes [44].  In 
these cells, activation of Wnt/β-catenin signaling stimulates osteoblastogenesis 
and inhibits adipogenesis by modulating the relative levels of cell type specific 
transcription factors [45].  While early reports indicated that Wnt signaling 
prevents induction of the master adipogenic regulators C/EBPα and PPARγ 
during preadipocyte differentiation, recent research demonstrates that transient 
activation of Wnt/β-catenin signaling rapidly suppresses these factors in 
bipotential ST2 cells, and that this suppression precedes the Wnt-induced 
increase in osteoblastogenic transcription factors [46].  Thus, while expression of 
inhibitory Wnts does not influence induction of the early adipogenic factors 
C/EBPβ or C/EBPδ [7,45,46], repression of C/EBPα and PPARγ appears to be a 
primary mechanism by which Wnt signaling controls mesenchymal cell fate.  
Farmer and colleagues have observed an additional relationship between β-
catenin and PPARγ in which these two factors functionally interact to negatively 
regulate each other’s activity (Fig. 1.1) [47,48]. 
 Wnt/β-catenin signaling has also been implicated in the balance between 
adipogenesis and myogenesis. Specifically, loss of Wnt10b in vivo owing to 
aging or targeted deletion leads to increased adipogenic potential of myoblasts 
and the acquisition of adipocyte characteristics during muscle regeneration 
[49,50].  Furthermore, conditional deletion of β-catenin in the developing mouse 
myometrium results in its conversion to adipose tissue [13], providing compelling 
evidence that the Wnt/β-catenin pathway is an important regulator of 
adipogenesis and mesenchymal cell fate in vivo.   
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β-catenin as a Central Mechanism for Inhibiting Adipogenesis 
 Although β-catenin was initially thought to function exclusively as a Wnt 
effector, it is now clear that binding occurs between β-catenin and signaling 
factors in other pathways, and that these interactions are important for cellular 
processes including adipogenesis.  For example, Cawthorn et al. demonstrated 
that suppression of C/EBPα and PPARγ by TNFα coincides with enhanced 
expression of several downstream targets of Wnt/β-catenin signaling (Fig. 1.1) 
[51].  Indeed, the authors reported that TCF7L2-dependent transcriptional activity 
is enhanced and β-catenin is stabilized during inhibition of adipogenesis by 
TNFα. Although stabilization of β-catenin still occurred, expression of dominant-
negative TCF7L2 completely blocked the inhibition of adipogenesis by TNFα, 
providing further support for downstream effectors of the Wnt pathway mediating 
cytokine-induced inhibition of differentiation [51,52].  
 Additional evidence of a central role for the Wnt/β-catenin pathway in 
adipogenesis comes from studies on liganded nuclear receptors.  In response to 
testosterone, androgen receptor binds β-catenin and shuttles it into the nucleus 
where it interacts with TCF/LEF transcription factors to inhibit adipogenesis (Fig. 
1.1) [53].  A distinct mechanism exists for the vitamin D receptor, which inhibits 
adipogenesis in bone marrow stromal cells at least in part by suppressing the 
expression of dickkopf-1 and SFRP2, secreted inhibitors of Wnt/β-catenin 
signaling [54].  Thus diverse signaling mechanisms converge on the Wnt/β-
catenin pathway directly through interaction with β-catenin, or indirectly through 
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regulated expression of factors that modulate Wnt/β-catenin signaling.  These 
data suggest that the Wnt/β-catenin pathway represents a major axis upon which 
various signals converge to influence preadipocyte differentiation. 
 
Conclusions 
 Since the initial report that Wnt/β-catenin signaling potently inhibits 
adipogenesis in cell culture models, there have been numerous advances 
illustrating the importance of this regulatory pathway in directing the fate of 
mesenchymal precursors.  While progress has been made with regard to the 
mechanisms underlying Wnt’s inhibition of adipogenesis and stimulation of 
osteoblastogenesis, questions remain that must be addressed to fully understand 
the roles of Wnt signaling in adipose tissue and bone biology.  Of particular 
importance will be studies aimed at understanding the cascade of events that 
occurs following activation of TCF/LEF by β-catenin. Future experiments will 
provide insight into whether the Wnt/β-catenin pathway is a viable target to 
improve human health. 
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Figure 1.1.  Wnt/β-catenin Signaling is a Central Pathway Regulating 
Adipogenesis.  Wnt/β-catenin signaling in preadipocytes is initiated by 
expression of Wnt10b, Wnt10a, and Wnt6.  Binding of these Wnts to 
transmembrane frizzled receptors and LRP coreceptors inhibits GSK3β leading 
to hypophosphorylation and stabilization of β-catenin in the cytoplasm.  β-catenin 
is then translocated to the nucleus where it binds TCF/LEF transcription factors 
and activates downstream targets to inhibit preadipocyte differentiation.  Factors 
from other inhibitory pathways converge on the Wnt/β-catenin pathway to block 
adipocyte conversion.  TNFα signals through its receptor, TNFα receptor-1, to 
stabilize β-catenin and activate downstream pathways.  Testosterone inhibits 
adipogenesis in part by stimulating interactions between androgen receptor and 
β-catenin.  This complex travels to the nucleus to promote β-catenin-mediated 
gene transcription.  DKK1 and Wnt5b are transiently induced during 
adipogenesis and stimulate preadipocyte differentiation.  DKK1 prevents Wnt 
signaling by inhibiting LRP coreceptors, while Wnt5b promotes differentiation 
through an unknown mechanism.  As adipogenesis proceeds, the expression of 
another Wnt inhibitor, Cby, is induced.  Cby binds β-catenin in the nucleus and 
prevents coactivation of TCF/LEF transcription factors.  Finally, binding of β-
catenin to PPARγ leads to rapid degradation of β-catenin through a mechanism 
that involves the proteosome.   (-) indicates factors that inhibit preadipocyte 
differentiation and (+) denotes factors that stimulate the process. 
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Chapter II 
A Role for sFRP5 in Adipocyte Biology and Obesity 
 
Abstract 
 Research conducted over the last decade has established the Wnt/β-
catenin signaling pathway as an important regulator of adipocyte differentiation.  
It is now known that preadipocytes secrete various Wnt proteins that act through 
an autocrine mechanism to inhibit preadipocyte differentiation.  Further 
complexity arises through the regulated expression of endogenous inhibitors of 
Wnt/β-catenin signaling, including the family of secreted frizzled-related proteins 
(sFRPs).  sFRPs are thought to prevent downstream Wnt signaling by binding to 
and sequestering Wnt molecules in the extracellular space, although recent 
reports have indicated sFRPs can function in roles independent of Wnt inhibition.  
Here we have sought to characterize a novel function for sFRP5 in adipocyte 
biology and obesity.  We show that sFRP5 expression is strongly induced during 
adipocyte differentiation in vitro and in various models of obesity.  Furthermore, 
sFRP5 expression is highly correlated with increasing adiposity and adipocyte 
size.  Mice that lack functional sFRP5 resist diet-induced obesity as evidenced by 
lower total body weight and decreased fat mass.  Detailed morphometric analysis 
revealed that sFRP5Q27stop mice challenged with a high fat diet have 
proportionally fewer large adipocytes than wild type mice, and using a model of 
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adipose tissue transplantation we show that sFRP5 regulates adipocyte size 
during obesity in a tissue autonomous manner.  In an attempt to elucidate the 
mechanism of action of sFRP5, we found that sFRP5 regulates adipocyte 
clustering of 3T3-L1 cells, a similar result to that observed upon activation of 
integrin signaling in adipocytes.  Indeed, we show that sFRP5 can functionally 
interact with integrins in a gel contraction assay, and that activation of the 
integrin/ERK signaling pathway is altered in two distinct models of sFRP5-
deficient adipocytes in culture.  Thus we provide evidence that sFRP5 regulates 
adipocyte expansion during obesity, and that the integrin/ERK cascade may 
mediate these effects. 
  
Introduction 
 Wnt signaling is a well-studied, critical component of numerous 
developmental and disease processes [1,2].  Despite our long-standing 
knowledge of this pathway’s impact on biology, discovery of novel downstream 
effectors and targets of Wnt signaling cascades continues to occur at a rapid 
pace.  Further complexity in the pathway arises from the identification and 
cloning of endogenous inhibitors of Wnt signaling, including the family of 
secreted frizzled-related proteins (sFRPs) [3-5].  The sFRP family consists of 
eight members, sFRP1-5, sizzled, sizzled2, and crescent, five of which are found 
in mammals (sFRP1-5) [3].  Studies aimed at characterizing sFRP function have 
focused on their role in modulating the Wnt pathway in vitro and in vivo and have 
provided evidence for direct interaction of sFRPs with Wnt ligands [6-9].  
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However, these interactions serve to further highlight the inherent complexity of 
the pathway as variable specificity and concentration dependent effects have 
been reported [6,7,10,11].   
 Support for the hypothesis that sFRPs function to suppress the Wnt 
pathway in vivo is found in a number of recent studies linking epigenetic 
inactivation of sFRP genes with various types of cancer [12-16].  For example, 
epigenetic loss of sFRP function has been shown to occur early in colorectal 
cancer progression, a disease in which 90% of cases are associated with 
mutations in Wnt pathway genes that result in increased accumulation of β-
catenin in the nucleus [12,17].  Moreover, restoration of sFRP function in 
colorectal cancer cells attenuates Wnt signaling even in the presence of 
downstream mutations, indicating that epigenetic inactivation of sFRP genes 
results in constitutive activation of Wnt signaling and promotion of cancer [12].  
 While this classical role for sFRPs is well documented, it is now clear that 
sFRPs also function across a broader range of cellular processes that may be 
independent of Wnt inhibition [18].  For example, sFRP1 has been reported to 
directly bind and activate Frizzled receptors 2, 4, and 7 [19,20].  Interestingly, 
sFRP2 has been shown to bind the fibronectin-integrin-α5β1 complex to promote 
cell adhesion and block apoptosis [21].  Additionally, sFRP1 can inhibit 
osteoclast formation by interacting with RANKL, preventing it from binding to 
RANK [22].  Furthermore, sizzled interacts with metalloproteinases, inhibiting 
their activity and leading to indirect inactivation of BMP signaling [23,24].  Thus, 
  21 
sFRPs appear to function in a variety of cellular events, often in concert with 
factors separate and distinct from known Wnt pathway components. 
 In the present study, we have evaluated the role of sFRP5 in adipocyte 
biology and obesity.  Previously Koza et al. reported that sFRP5 is expressed in 
adipocytes and correlated with increasing weight gain [25].  Here we extend 
those findings to show that sFRP5 expression is induced during adipocyte 
differentiation and highly correlated with increasing adiposity and relative 
adipocyte size in multiple models of obesity.  Moreover, we demonstrate that 
mice lacking functional sFRP5 resist diet-induced obesity and exhibit a decrease 
in fat mass.  Using quantitative histological methods, we observed that sFRP5 
regulates adipocyte size during obesity in a tissue dependent manner, thus 
revealing a novel role for sFRP5 in the pathology of adipose tissue.  Further 
investigation into the mechanism of action of sFRP5 in adipocytes revealed a 
functional interaction between sFRP5 and integrin signaling.  We found that 
sFRP5-mediated collagen gel contraction is dependent on functional integrin β1 
and that activation of downstream effectors of the integrin/ERK pathway is 
altered in adipocytes lacking sFRP5.  We conclude that sFRP5 plays an 
important role in regulating adipocyte growth during the development of obesity.    
 
Materials and Methods 
Animals 
 Animal care was overseen by the Unit for Laboratory Animal Medicine 
(University of Michigan).  LXRβ -/- mice were generated by gene targeting and 
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have been described previously [26].  sFRP5Q27stop mice were generated by ENU 
mutagenesis in which a C79T mutation created a premature stop codon at Gln 
27, likely producing a null allele [27].  All animals were housed with a regular 12-
hour light/dark cycle and were fed ad libitum with standard rodent chow diet 
(Laboratory Rodent Diet 5001, LabDiet, St. Louis, MO).  Where indicated, mice 
received ad libitum access to a low fat diet (10% fat, D12450B, Research Diets 




 Mouse 3T3-L1 preadipocytes and human embryonic kidney 293T cells 
were maintained in Dulbecco's modified Eagle's medium (GIBCO) containing 
10% calf serum (Atlanta Biologicals) as described previously [28].  3T3-L1 cells 
were induced to differentiate into adipocytes two days after confluence as 
described previously, using methylisobutylxanthine, dexamethasone, and insulin 
(MDI) [29]. 
 
eMSC Isolation and Culture 
 Ear mesenchymal stem cells were harvested from wild type and 
sFRP5Q27stop mice as previously described [30].  eMSCs were maintained in 5% 
CO2 and DMEM/F12 1:1 media (GIBCO) supplemented with 15% fetal bovine 
serum (Atlas Biologicals), Primocin antibiotics (Invivogen, San Diego, CA) and 
20ng/ml recombinant bFGF (R&D Systems).  To induce adipocyte differentiation, 
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recombinant bFGF was removed and replaced with MDI as described for 3T3-L1 
cells above plus 5 µM troglitazone. 
 
Plasmids 
 sFRP5 was amplified from a mouse eye cDNA library using forward and 
reverse primers containing 5’ EcoR1 and 3’ Xho1 restriction sites, respectively.  
For the sFRP5-myc fusion construct, the myc tag sequence was inserted 
immediately upstream of the Xho1 site in the reverse primer so as to be at the C 
terminus of the protein.  The resulting amplicons were cloned into the EcoR1 and 
Xho1 sites of pcDNA3.1+ (Invitrogen) to generate pcDNA3.1+(sFRP5) and 
pcDNA3.1+(sFRP5-myc) constructs.  sFRP5 and sFRP5-myc were further 
subcloned into the pMSCVneo retroviral vector (Clontech) using the EcoR1 and 
Xho1 sites for subsequent stable infection into 3T3-L1 preadipocytes.   
 
Transfections and Infections 
 For sFRP5 localization studies, 293T cells were transiently transfected 
with pcDNA3.1+(sFRP5-myc) using a calcium phosphate coprecipitation method 
as previously described [31].  Retroviral infection and selection procedures were 
performed essentially as described [32].  Briefly, 293T cells were transfected by 
calcium phosphate coprecipitation as above.  About 16 hours after transfection 
virus-containing media was collected, passed through a 0.45-µm syringe filter, 
and combined with polybrene (hexadimethrine bromide; Sigma-Aldrich, St. Louis, 
MO) to a final concentration of 8 µg/ml.  This media was then applied to 
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subconfluent (25-40% confluent) 3T3-L1 preadipocytes.  The infection protocol 
was repeated every 12 hours until cells were approximately 80% confluent.  3T3-
L1 cells were then split 1:5 in Dulbecco's modified Eagle's medium (GIBCO) 
supplemented with 10% calf serum and appropriate selection agents (400 µg/ml 
neomycin or 2 µg/ml puromycin).  Once fully selected, stably infected cells were 
used for the appropriate assays.  
 
Stable Knockdown of sFRP5 in 3T3-L1 cells 
 Two independent methods were used to knockdown sFRP5 in 3T3-L1 
cells.  First, four separate shRNA constructs targeting sFRP5 were designed and 
cloned into the pSUPERIOR.retro.puro retroviral vector from OligoEngine 
(Seattle, WA) as previously described [31].  Two of these constructs, sFRP5(1) 
(puromycin resistant) and sFRP5(4) (neomycin resistant) were co-infected into 
3T3-L1 preadipocytes to created a stable cell line that achieve ~90% knockdown 
of sFRP5.  Co-infected cells were selected and maintained in double selection 
DMEM media (400 µg/ml neomycin and 2 µg/ml puromycin) supplemented with 
10% calf serum.  Second, four independent shRNA constructs targeting sFRP5 
were purchased from OriGene (Rockville, MD).  Stable infection with construct 
sFRP5(sh3) achieved ~85% knockdown of sFRP5 in 3T3-L1 cells compared to 
cells expressing the GFP control vector.   
 
Gel Contraction 
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 For collagen gel contraction studies, subconfluent 3T3-L1 preadipocytes 
were incubated with an integrin β1 blocking antibody (Ha2/5) or IgM isotype 
control (G235-1, BD Biosciences) for one hour.  To obtain free-floating gels, 12 
well culture dishes were pre-treated with 1% BSA in PBS.  3T3-L1 preadipocytes 
expressing sFRP5 or empty vector were trypsinized and resuspended in a type I 
collagen matrix (rat tail collagen type I, BD Biosciences) at a concentration of 
500,000 cells/ml according to manufacturers instructions.  Gels were allowed to 
polymerize for 30 minutes at 37oC, after which 3T3-L1 media containing blocking 
antibody or IgM control were added.  Collagen gel contraction was monitored at 
various time points over a 72-hour period and quantified using ImageJ software 
(http://rsb.info.nih.gov/ij/).  Percent contraction was quantified by dividing the 
area of the contracted gel by the area of the well and expressed as a percent.     
 
Localization of sFRP5 
 Separation of whole cell, ECM, and conditioned media fractions was 
performed based on the method of Lee [21].  Briefly, 293T cells were treated with 
or without 10 µg/ml heparin (Sigma-Aldrich, St. Louis, MO) for 4-6 hours.  
Subsequently, conditioned media were concentrated by centrifuging at 3000 x g 
for 15 min using Centriprep filter devices (Millipore, Billerica, MA).  Confluent 
cells were then released from the culture dishes by incubating with 5 mM EDTA 
in PBS.  The remaining ECM components were washed with PBS and extracted 
with Western lysis buffer (1% SDS, 60 mM Tris pH 6.8, and protease inhibitors).   
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Immunoblotting 
 Protein concentrations were determined using Protein Assay Solution 
(Bio-Rad, Hercules, CA).  Proteins were separated by SDS-PAGE and 
transferred to nitrocellulose membranes.  Immunoblotting was performed 
essentially as described [32] using anti-Myc-horseradish peroxidase (Invitrogen), 
p-FAK, p-ERK1/2, total ERK1/2 (Cell Signaling) antibodies. 
 
Adipocyte Isolation 
 Isolation of preadipocyte-containing stromal vascular and adipocyte 
fractions was performed as previously described [33,34]. 
 
Quantitative RT-PCR 
 Total RNA from adipose tissue or 3T3-L1 cells was extracted using RNA 
Stat60 (Tel-Test, Friendswood, TX) and then purified using RNeasy mini-kits 
(Qiagen, Valencia, CA).  cDNA was synthesized using the TaqMan system 
(Applied Biosystems, Foster, CA) and random hexamer primers.  Quantitative 
PCR was performed according to the manufacturer's protocol.  SYBR Green I 
was used to monitor amplification of DNA on the iCycler and IQ real-time PCR 
detection system (Bio-Rad Laboratories).  Gene expression was normalized to 
cyclophilin mRNA or 18S rRNA levels as indicated. 
 
Dual Energy X-ray Absorptiometry 
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 Wild type and sFRP5Q27stop mice were anesthetized using inhaled 
isoflurane and scanned using the PIXImus2 Mouse Densitometer (GE Medical 
Systems, Madison, WI).  System software estimated fat mass, lean mass, and 
bone mineral content for each mouse. 
 
Blood Chemistry 
 Whole blood was collected from the saphenous vein of random fed wild 
type and sFRP5Q27stop mice on either a normal chow or high fat diet.  Plasma was 
then prepared and stored at –80°C until assayed.  Insulin, leptin, and other 
adipokines were simultaneously measured on a Luminex 100 machine using the 
Lincoplex mouse serum adipokine kit according to the manufacturer’s protocol 
(Linco Research, St. Charles, MO). 
 
Glucose Tolerance Test 
 To test glucose tolerance, wild type and sFRP5Q27stop mice were given an 
intraperitoneal injection of 1.5 mg glucose/g body weight after a 12-hour fast.  
Blood glucose was determined at the indicated times from tail blood using the 
OneTouch Ultra glucometer (Lifescan, Burnaby, Canada). 
 
Adipocyte Histology 
 Gonadal white adipose tissue was dissected from wild type and 
sFRP5Q27stop mice that had received transcardial perfusions with 4% 
paraformaldehyde.  The tissue was maintained in additional fixative for 24 hours.  
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After embedding in paraffin, adipose tissue sections were stained with 
hematoxylin and eosin.  Images were taken on an Olympus BX-51 microscope 
with an Olympus DP70 color digital camera.  Adobe Photoshop was used to 
enhance the contrast of the images before analysis.  Integrated morphometry 
analysis was used to calculate cellular cross sectional area and the number of 
adipocytes per field using MetaMorph software (version 6.1; Molecular Devices, 
Downingtown, PA). 
 
Adipose Tissue Transplantation 
 Gonadal while adipose tissue was excised from wild type and sFRP5Q27stop 
donor mice and transplanted subcutaneously into db/db recipient mice at four 
weeks of age.  To control for host differences in hyperphagia, vasculature 
formation, or other variables, 100 mg pieces of tissue from two wild type and two 
sFRP5Q27stop mice were transplanted into the same db/db recipient.  After 10 
weeks, the transplanted tissue was harvested and fixed in 4% paraformaldehyde 
for 24 hours.  Hematoxylin and eosin stained sections were subjected to 
morphometric analysis as described above. 
 
Food Intake 
 Mice on a high fat diet were housed individually in microisolator cages and 
acclimated for at least seven days.  Food consumption was measured every 
other day for one week. 
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Fecal Lipid Content 
 Fecal pellets were collected and frozen (-20oC) until analysis. For the 
analysis of fecal lipid, pellets were put in pre-weighed tins, and heated at 60oC 
for up to 2 hours, or until dry weight was reached.  The pellets were crushed into 
a fine powder with a mortar and pestle.  Fecal lipid was extracted according to 
the method of Folch [35]. Briefly, one gram of fecal powder was gently mixed 
overnight using 10 ml of chloroform:methanol (v:v, 2:1).  The following day, the 
tube contents were gravity filtered (Whatman no. 1) and rinsed with 3 ml of fresh 
chloroform:methanol (v:v, 2:1).  We added 1 ml sterile H2O to the collected 
solvent, then mixed the tubes vigorously and allowed them to sit overnight to 
permit layer separation.  The following day, the top water layer was carefully 
removed, and the organic layer containing lipid was added to a pre-weighed tin.  
The chloroform and methanol were then allowed to volatilize and the remaining 
lipid was quantified by weighing. 
 
Metabolic Profiling 
 After acclimating to the appropriate conditions for one week, oxygen 
consumption, carbon dioxide production, respiratory quotient, and activity were 
measured in wild type and sFRP5Q27stop mice using a comprehensive lab animal 
monitoring system at the Michigan Metabolomics and Obesity Center at the 
University of Michigan.  Readings were taken for three days.  VO2 and VCO2 
data were normalized to lean body mass. 
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Results 
Expression and Localization of sFRP5 In Vitro and In Vivo 
 To determine whether sFRPs are regulated during adipogenesis, we 
analyzed expression of sFRP1-5 during a time course of 3T3-L1 preadipocyte 
differentiation.  We found that two members of the sFRP family, sFRP2 and 
sFRP5, showed dynamic expression patterns.  sFRP2 mRNA is expressed at 
maximal levels in confluent preadipocytes then rapidly downregulated upon 
induction of adipogenesis.  Conversely, sFRP5 mRNA expression is induced 
during adipogenesis, reaching maximal expression six days after initiation of 
differentiation (Figure 2.1a).  Consistent with our in vitro findings and in 
agreement with published reports, sFRP5 mRNA is expressed predominantly in 
the adipocyte fraction of adipose tissue (Figure 2.1b) [25].  
 sFRP1 and sFRP2 are thought to act locally by remaining tightly 
associated with the extracellular matrix (ECM) [6,21].  To determine whether 
sFRP5 exhibits similar extracellular localization, 293T cells were transiently 
transfected with pcDNA3.1+ vector or vector expressing an sFRP5-myc fusion 
protein.  To achieve separation of whole cell and ECM fractions, transfected cells 
were treated with 5 mM EDTA to detach cells from the culture dish without 
destroying the underlying ECM.  Whole cell, ECM, and conditioned media 
fractions were collected and subjected to immunoblot analysis.  sFRP5 protein 
was detected in the whole cell and ECM fractions but not in the conditioned 
media (Figure 2.1c).  In agreement with previous studies on sFRP1 localization 
[6], sFRP5 is liberated from the ECM by addition of exogenous heparin and can 
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subsequently be detected in the conditioned media (Figure 2.1c).  Similar results 
are also observed in 3T3-L1 adipocytes stably expressing sFRP5 (data not 
shown).  These data suggest that upon secretion from the cell, sFRP5 is 
incorporated into the ECM and likely functions in an autocrine or paracrine 
manner. 
 
sFRP5 is Associated with Increasing Adiposity and Adipocyte Size 
 To determine whether sFRP5 expression is altered during obesity, we 
evaluated sFRP5 mRNA levels across a range of diet-induced and genetically 
obese mouse models.  Quantitative RT-PCR analysis of RNA from white adipose 
tissue of C57BL/6J mice fed either a low fat or a high fat diet for six months 
revealed that sFRP5 expression is increased 25 fold in high fat-fed mice (Figure 
2.2d).  sFRP5 levels are also increased in white adipose tissue from leptin-
deficient ob/ob mice [eight fold] (data not shown) and in mice that have become 
obese following ovariectomy (Figure 2.2b).  sFRP5 expression displays a strong 
positive correlation with percent body fat in high fat diet (R2=0.8426) and 
ovariectomized models (R2=0.7579), (Figure 2.2a,b).  In contrast, sFRP2 
expression is neither increased during obesity nor correlated with increasing 
adiposity (Figure 2.2a).  Thus sFRP5 is specifically upregulated during obesity 
and displays a strong correlation with increasing adiposity. 
 As obesity is characterized in part by adipocyte hypertrophy, we sought to 
examine the relationship between sFRP5 expression and adipocyte size.  We 
analyzed histological sections of white adipose tissue from C57BL/6J mice 
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challenged with a high fat diet and found that adipocytes from these mice were 
approximately two times larger than those from mice fed a low fat diet (data not 
shown).  When sFRP5 expression was compared with relative adipocyte size, we 
found that the two variables were highly correlated (Figure 2.2c).  Leptin, which is 
known to be increased in relation to adipocyte size, and sFRP2 are also shown 
for comparison (Figure 2.2c). 
 Finally, we examined sFRP5 expression in adipose tissue from LXRβ -/- 
mice, as adipocytes from these mice do not undergo diet-induced hypertrophy.  
Importantly, we found that sFRP5 expression was not increased in LXRβ -/- mice 
challenged with a high fat diet (Figure 2.2d).  Taken together, the results of these 
studies suggest a strong positive relationship between sFRP5 expression and 
adipocyte size. 
 
sFRP5Q27stop Mice Resist Diet-Induced Obesity and Display a Reduction in 
Fat Mass 
 To evaluate the role of sFRP5 in adipocyte biology and obesity in vivo, we 
obtained sFRP5Q27stop mice that were generated by ENU mutagenesis in which a 
single base pair mutation resulted in a premature stop codon at glutamine 27, 
likely creating a nonfunctional allele (Figure 2.3a) [27].   
 sFRP5Q27stop mice are indistinguishable from wild type mice under 
standard chow-fed conditions as assessed by total body weight, body 
composition, tissue weights,  metabolic phenotyping [plasma insulin, VO2, VCO2, 
respiratory quotient], and analysis of secreted adipokines [leptin and resistin] 
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(data not shown).  Therefore, we sought to investigate the role of sFRP5 in 
obesity by challenging 12-16 week old sFRP5Q27stop mice with a high fat diet.  We 
found that sFRP5Q27stop mice resist diet-induced weight gain compared to high 
fat-fed wild type mice (Figure 2.3b).  Analysis of body composition by Dual 
Energy X-Ray Absorptiometry (DEXA) revealed that the difference in total body 
weight is due solely to a decrease in fat mass in sFRP5Q27stop mice, as lean 
mass, bone mineral content, and organ weights are nearly identical between 
genotypes (Figure 2.3c, data not shown).  Consequently, sFRP5Q27stop mice have 
a lower percent body fat compared to controls (Figure 2.3d).  Furthermore, 
analysis of random fed blood variables by ELISA revealed that plasma leptin and 
plasma insulin are decreased in sFRP5Q27stop mice compared to wild type 
controls (Figure 2.3e).  These differences presumably reflect an increase in leptin 
and insulin resistance in the obese wild type mice, and also serve as further 
evidence of decreased fat mass in sFRP5Q27stop mice.   
 To determine whether glucose homeostasis was altered in sFRP5Q27stop 
mice, we performed a glucose tolerance test.  High fat-fed wild type and 
sFRP5Q27stop mice were fasted for 12 hours, after which glucose was injected 
intraperitoneally.  There were no significant differences in fasted blood glucose or 
glucose tolerance in sFRP5Q27stop mice (Figure 2.3f).  While sFRP5Q27stop mice 
are able to clear glucose to the same extent as wild type mice, lower levels of 
plasma insulin in fed mice suggest that sFRP5Q27stop mice are more insulin 
sensitive than wild type mice.   
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 Taken together, these results show that sFRP5Q27stop mice resist diet-
induced weight gain and that this effect is due to alterations in fat mass. 
 
sFRP5 Regulates Adipocyte Size During Obesity in a Tissue Autonomous 
Manner 
 Based on our previous findings that sFRP5 mRNA expression is highly 
correlated with increasing adipocyte size (Figure 2.2c,d), we hypothesized that 
the observed decrease in fat mass in sFRP5Q27stop mice on a high fat diet would 
be associated with alterations in adipocyte hypertrophy.  To test this hypothesis 
we performed histological analyses on gonadal white adipose tissue (G-WAT) 
from wild type and sFRP5Q27stop mice that had been challenged with a high fat 
diet for six weeks.  In agreement with our previous observations of body 
composition using DEXA, we found that G-WAT from sFRP5Q27stop mice weighed 
less than G-WAT from wild type mice (Figure 2.4a).  In order to obtain a more 
comprehensive histological view of gonadal adipose tissue in these mice, we 
divided the tissue into four separate quadrants, with quadrant 1 being most 
proximal to the epididymis and quadrant 4 the most distal section of tissue 
(Figure 2.4b).   
 While our earlier analysis of relative adipocyte size was determined by 
quantifying the number of adipocytes in a given microscopic field, we wished to 
obtain a more accurate representation of adipocyte cross-sectional area.  Using 
MetaMorph software (Molecular Devices) we were able to precisely calculate 
adipocyte size from hematoxylin and eosin stained sections of G-WAT from wild 
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type and sFRP5Q27stop mice.  This analysis revealed that there were 
proportionally fewer large adipocytes in sFRP5Q27stop G-WAT compared to 
controls, with the 53% difference between wild type and sFRP5Q27stop adipocytes 
in quadrant 3 being statistically significant (Figure 2.4c).  Here we define large 
adipocytes as cells greater than 8000 µm2.  These large adipocytes, while rarely 
seen under standard chow-fed conditions, make up a substantial percentage of 
the adipose tissue volume under conditions of obesity.  Thus, the differences 
observed here are likely to have a significant effect on the overall volume and 
weight of the adipose tissue of wild type and sFRP5Q27stop mice. 
 Another observation stemming from our histological analysis involved the 
frequency with which crown-like structures (CLS) were seen in wild type and 
sFRP5Q27stop mice.  The term CLS is used to describe a ring or crown of 
macrophages surrounding a single adipocyte.  These macrophages are thought 
to consume dead or dying adipocytes and are a marker of macrophage infiltration 
and inflammation associated with obesity [36].  Interestingly, we found fewer CLS 
in G-WAT from sFRP5Q27stop mice compared to wild type controls, with the 
difference in quadrant 3 again being statistically significant, and trending toward 
significance in quadrant 4 (Figure 2.4d).  These findings provide some evidence 
to suggest that obesity-associated inflammation and macrophage infiltration may 
be decreased in sFRP5Q27stop mice compared with controls. 
 To investigate whether alterations in adipocyte size in sFRP5Q27stop mice 
were tissue autonomous or simply a reflection of the overall adiposity of the 
animal, we performed an adipose tissue transplant experiment.  G-WAT from 
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wild type and sFRP5Q27stop mice was dissected and transplanted subcutaneously 
into db/db recipient mice at four weeks of age (Figure 2.4e).  The contralateral G-
WAT depot was also dissected and used as a baseline standard in subsequent 
histological analyses.  As expected, the db/db recipient mice rapidly became 
obese and induced hypertrophy of adipocytes in the newly vascularized 
transplanted tissue.  Ten weeks after transplantation, the donor tissue was 
excised and subjected to histological processing and MetaMorph analysis.  
Consistent with previous data, the results of this experiment revealed a 30% 
decrease in the proportion of large adipocytes in sFRP5Q27stop G-WAT compared 
to wild type controls, whereas there were virtually no cells greater than 8000 µm2 
in either wild type or sFRP5Q27stop G-WAT before transplantation (Figure 2.4f).  
Thus, we conclude that loss of sFRP5 limits the ability of adipocytes to expand 
during obesity.   
 Taken together, our histological and morphometric analyses indicate that 
sFRP5 regulates adipocyte size during obesity in a tissue autonomous manner. 
 
Relative Expression of Vasculature and Adipocyte Markers in sFRP5Q27stop 
Mice 
 Neovascularization in adipose tissue is a critical event during development 
of adipose tissue and obesity, ensuring that expanding adipocytes meet their 
requirements for oxygen and essential nutrients [37].  Therefore, one plausible 
cause of resistance to adipocyte hypertrophy in sFRP5Q27stop mice may be due to 
lack of formation of vascular networks needed by adipocytes undergoing 
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hypertrophy.  To test whether there may be altered vasculature formation in 
sFRP5Q27stop mice, we analyzed adipose tissue expression of various modulators 
of vasculature maturation.  We found that there were no differences in 
expression of angiopoietin-1, a factor thought to play a crucial role in vascular 
remodeling in obesity [38] (Figure 2.5a).  Similarly, levels of angiopoietin-2, 
receptor tyrosine kinases Tie-1 and Tie-2, and smooth muscle alpha actin 
(ACTA2) were not different in sFRP5Q27stop mice compared to wild type controls 
(Figure 2.5a).  In addition, analysis of hematoxylin and eosin stained histological 
sections of adipose tissue from these mice showed no change in the frequency 
of large vessels (data not shown).  Thus, our data suggest that vascular 
formation is not altered in sFRP5Q27stop mice and likely does not contribute to 
changes in adipocyte size in this model. 
 To test whether the degree of preadipocyte recruitment is altered in 
adipose tissue from sFRP5Q27stop mice, we analyzed mRNA expression of 
adipocyte markers and found that PPARγ, KLF15, and leptin levels are all 
unchanged compared to wild type mice (Figure 2.5b).  These data suggest that a 
similar level of adipogenesis occurs in both wild type and sFRP5Q27stop mice.  
 Finally, we examined mRNA expression of sFRP1, sFRP2, and sFRP5 in 
adipose tissue from wild type and sFRP5Q27stop mice, as these genes comprise a 
subgroup of sFRPs that are highly related with regard to genetic structure.  Our 
data indicate that sFRP5 mRNA is substantially downregulated in sFRP5Q27stop 
mice; however, we found no compensatory upregulation of sFRP1 or sFRP2 
transcripts in response to an apparent lack of sFRP5 function (Figure 2.5c).  
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While it appears that regulation of sFRP1 and sFRP2 mRNA is unchanged in 
sFRP5Q27stop mice, we cannot rule out the possibility that endogenous levels of 
one or both of these factors may be playing a functionally redundant role to that 
of sFRP5 in this context [8]. 
 
Metabolic Phenotype of Mice Harboring the sFRP5Q27stop Mutation 
 In an attempt to clarify the underlying cause of obesity resistance 
observed in mice homozygous for the sFRP5Q27stop mutation, we evaluated food 
intake and fat absorption in sFRP5Q27stop mice.  Food intake was measured in 
individually housed mice for one week.  Our results indicate that food intake is 
not changed in sFRP5Q27stop mice relative to their wild type counterparts (Figure 
2.6a).  In contrast, the total amount of fat excreted in the feces of sFRP5Q27stop 
mice was significantly increased by approximately 10% compared to controls 
(Figure 2.6b).  However, calculations of food intake and feed efficiency suggest 
that this modest increase in excreted lipid cannot account solely for the 
difference in fat mass and body weight seen over a five-week period in 
sFRP5Q27stop mice (Figure 2.3b). 
 We next sought to characterize whether metabolic parameters were 
altered in sFRP5Q27stop mice compared to wild type controls.  Mice from both 
groups were acclimated to the appropriate environmental conditions and 
afterward subjected to various metabolic measurements in a comprehensive lab 
animal monitoring system (CLAMS).  We found that, despite a decrease in fat 
mass in sFRP5Q27stop mice, differences in oxygen consumption were not 
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observed between the two groups (Figure 2.6c).  Unexpectedly, however, carbon 
dioxide production was significantly lower in sFRP5Q27stop mice, while respiratory 
quotient was not altered between genotypes (Figure 2.6d,e).  Activity of the mice 
was also measured and was not found to be different between sFRP5Q27stop mice 
and wild type control animals (Figure 2.6f).   
 Though our attempts to clarify the mechanism of obesity resistance in 
sFRP5Q27stop mice remain incomplete, the results obtained herein suggest that in 
general, the metabolic profile of sFRP5Q27stop mice is not substantially altered 
compared to wild type controls. 
 
Integrin Signaling may Mediate sFRP5-Regulated Adipocyte Clustering 
 To further elucidate the role of sFRP5 in adipocyte biology we turned to 
cell culture-based models, utilizing both well-characterized and newly established 
approaches.  Using retroviral delivery, we enforced ectopic expression of sFRP5 
in 3T3-L1 preadipocytes but failed to detect any effect on differentiation, as cells 
infected with pMSCV empty vector or vector driving expression of sFRP5 showed 
no differences in lipid accumulation or mRNA expression of adipogenic 
transcription factors, PPARγ and C/EBPα (data not shown).  One notable 
difference, however, was observed after the cells had differentiated into 
adipocytes.  Cells overexpressing sFRP5 form larger and more numerous 
adipocyte clusters than control cells (Figure 2.7a).  Adipocyte clusters are seen 
under the microscope as darker regions representing multiple layers of cells.  
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Interestingly, using stably expressed short hairpin RNA (shRNA) molecules to 
inhibit sFRP5 function in 3T3-L1 cells, we observed the opposite effect.  
Adipocytes expressing sFRP5 at 10% of physiological levels exhibit substantially 
decreased adipocyte clustering (Figure 2.7a).  Moreover, a thickened area of 
fluorescence surrounds many of the cells in the monolayer, making single cells 
appear even more separate and distinct (Figure 2.7a).  To extend this finding, we 
performed an adipocyte aggregation experiment in which 3T3-L1 adipocytes 
expressing either a scrambled control or two shRNA molecules against sFRP5 
were detached from the culture dish and re-plated on regular plastic dishes or 
dishes coated with ECM components (fibronectin, collagen type I, or collagen 
type IV).  Consistent with previous results, control adipocytes readily form large 
aggregates upon re-plating, while sFRP5-deficient adipocytes completely fail to 
form aggregates, and instead adhere to the substratum as mostly single cells 
(Figure 2.7b).  Figure 2.7 illustrates the effect of adipocytes re-plated on collagen 
type IV coated plates; however, similar results were obtained using uncoated or 
collagen type I coated plates (data not shown).  Thus, our data support a role for 
sFRP5 in clustering of adipocytes in vitro, and suggest that sFRP5 may be 
involved in cell-cell or cell-ECM interactions. 
 Integrins are known to play a significant role in adhesion of cells with other 
cells or with the surrounding matrix [39].  Of particular interest to our study are 
recent results showing that integrins are required for clustering of 3T3-L1 
adipocytes [40].  In light of this recent finding, we sought to determine whether 
the sFRP5 and integrin pathways interact utilizing a model of 3D collagen gel 
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contraction, which has been shown to be dependent on integrin function [41,42].  
3T3-L1 preadipocytes expressing either pMSCV empty vector or vector 
expressing ectopic sFRP5 were embedded in a 3D collagen gel at a 
concentration of 500,000 cells/ml.  Gels were monitored for several days and the 
amount of gel contraction was calculated at various time points.  The results of 
this study indicate that cells expressing sFRP5 are able to contract a collagen gel 
at a greater rate than control cells (Figure 2.7c).  To determine whether this effect 
is mediated by integrins, we performed the same experiment in the presence or 
absence of an integrin β1 blocking antibody (Ha2/5).  As expected, the rate at 
which sFRP5-expressing cells treated with IgM control antibody contracted the 
collagen gels was increased compared to controls.  However, treatment with the 
integrin β1 blocking antibody abolished this effect (Figure 2.7c).  Thus, the gel-
contracting ability of sFRP5-expressing 3T3-L1 preadipocytes is dependent on 
functional integrin β1. 
 To explore the relationship between sFRP5 and integrin signaling in 
adipocytes, we analyzed the activation status of known integrin pathway 
components in multiple in vitro models where the level of endogenous sFRP5 
was decreased.  The integrin/ERK cascade has been reported to play a role in 
the adaptation of adipocyte function to changes in cell size [43]; therefore we 
sought to examine the activity of this pathway in our system.  In 3T3-L1 cells 
stably expressing shRNA constructs against sFRP5, we found that ERK1/2 
phosphorylation is substantially increased (Figure 2.7d).  A similar result was 
observed in sFRP5Q27stop primary ear mesenchymal stem cells (eMSCs) that 
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were expanded and differentiated in vitro (Figure 2.7d).  To extend our findings, 
we examined the phosphorylation state of focal adhesion kinase (FAK), a primary 
effector of integrin signaling activated by integrin clustering at the plasma 
membrane.  In support of a positive relationship between sFRP5 and integrins, 
we found that phosphorylation of FAK at tyrosine 925 was decreased in sFRP5-
deficient 3T3-L1 adipocytes and sFRP5Q27stop eMSCs (Figure 2.7d).  Taken 
together, these data suggest that sFRP5 influences adipocyte clustering, and 
that this may involve sFRP5-mediated alterations in integrin signaling.    
 
Discussion 
 Here we show that sFRP5 expression is induced during adipocyte 
differentiation in vitro and in animal models of obesity.  Furthermore, sFRP5 
expression is highly correlated with increasing percent body fat and adipocyte 
size.  Mice that lack functional sFRP5 resist diet-induced obesity as evidenced by 
lower total body weight and decreased fat mass.  Detailed histological analysis 
revealed that sFRP5Q27stop mice challenged with a high fat diet have 
proportionally fewer large adipocytes than wild type mice, and using a model of 
adipose tissue transplantation we subsequently found that sFRP5 regulates 
adipocyte size during obesity in a tissue autonomous manner.   
 These data support a model wherein sFRP5 expression is increased in 
adipocytes as they expand during obesity.  In this model, sFRP5 itself further 
influences adipocyte growth as hypertrophy occurs to facilitate increased lipid 
load (Figure 8a).  In addition, sFRP5 may act to inhibit autocrine Wnt signaling in 
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surrounding preadipocytes, thus allowing for their recruitment and differentiation 
under conditions of increased lipid accumulation, such as obesity (Figure 8a).   
 We analyzed the metabolic profile of sFRP5Q27stop mice in an attempt to 
determine the cause of obesity resistance and reduced fat mass in these animals 
under conditions of high fat challenge.  However, our analysis of metabolic 
parameters in sFRP5Q27stop mice yielded no substantial differences in oxygen 
consumption, respiratory quotient, activity, or food intake compared to wild type 
mice.  Thus, we conclude that obesity resistance in sFRP5Q27stop mice is not the 
result of altered whole body metabolism.  We have not ruled out, however, that 
undetected differences in local metabolism may have significant cumulative 
effects on fat mass and body weight over time.  Additionally, as we predict 
sFRP5 function to be disrupted in all tissues of sFRP5Q27stop mice, it is 
conceivable that the observed phenotype stems from effects in other parts of the 
body.  Our finding that sFRP5Q27stop mice excrete a modest but significantly 
higher amount of lipid than wild type mice suggests there may be malabsorption 
of lipid in the gut and lends credence to this hypothesis.   
 While it is clear that there are multiple factors involved, further studies are 
needed to determine how important changes in metabolism and energy balance 
are to the reduction of fat mass in high fat-challenged sFRP5Q27stop mice. 
 The finding that creation of large adipocytes is limited in sFRP5Q27stop mice 
suggests that sFRP5 regulates adipocyte growth during obesity.  While this 
observation provides some insight into the cause of obesity resistance in 
sFRP5Q27stop mice, the mechanism by which sFRP5 influences the creation of 
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large adipocytes remains to be elucidated.  Several factors could potentially be 
involved.  As mentioned above, the expansion of adipocytes during development 
of obesity requires the formation of new vasculature to provide necessary 
nutrients and oxygen to the cells [37].  Thus, one possible mechanism involves 
adipocyte-derived sFRP5 signaling in a paracrine manner to recruit new vessels 
into the expanding adipose depot.  An increasing number of reports have shown 
that Wnt signaling components play a central role in neovessel formation in 
different tissues [44,45].  Interestingly, a recent study found that sFRP1 
increases the formation of new vasculature in the mouse hindlimb after an 
ischemic event [20].  While these findings seem to support the notion that sFRP5 
may function in a similar role, to our knowledge no studies have been reported 
suggesting a role for Wnt signaling in neovascularization of adipose tissue during 
obesity.  Moreover, our analysis of adipose tissue mRNA showed no differences 
in expression of factors involved in vasculature formation between wild type and 
sFRP5Q27stop mice (Figure 2.5a).  Additionally, there were no differences in the 
frequency of large vessels in adipose tissue from sFRP5Q27stop mice, although we 
cannot rule out the possibility of altered microvasculature formation that was not 
detected by our methods.  Thus, based on our data we conclude that sFRP5 
does not influence vascularization of adipose tissue during development of 
obesity.   
 Another event that may limit the creation of large adipocytes in 
sFRP5Q27stop mice involves remodeling of the ECM.  It stands to reason that the 
cage-like ECM surrounding each adipocyte must be significantly remodeled to 
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allow the cells to expand and accumulate lipid.  Indeed, studies have shown that 
adipocyte growth and expansion in vivo and in 3D cell culture conditions is 
severely diminished in mice and cells lacking MT1-MMP, a membrane-anchored 
metalloproteinase involved in collagen degradation [46].  Based on our data that 
sFRP5 expression is dramatically increased in relation to adipocyte size and that 
sFRP5 is localized to the ECM upon secretion from the cell, it is tempting to 
speculate that sFRP5 may be involved in breakdown and remodeling of the ECM 
during adipocyte hypertrophy, particularly as sizzled has been shown to interact 
with metalloproteinases in vertebrates [23,24].  Furthermore, sFRP5 contains a 
netrin (NTR) domain similar to that found in tissue inhibitors of 
metalloproteinases (TIMPs), which are known to regulate activity of ECM 
remodeling proteins [47].  Despite these intriguing parallels, we have no evidence 
to suggest that sFRP5 is directly involved in ECM remodeling.  Future studies to 
test this hypothesis should focus on characterizing the activity of matrix 
remodeling factors, such as matrix metalloproteinases (MMPs), under conditions 
of altered sFRP5 expression, since mRNA expression of these factors would not 
necessarily be altered.   
 Our finding that sFRP5 can interact with the integrin/ERK pathway may 
shed further light on the mechanism by which adipocytes expand during obesity.  
While little is known with regard to classical functions of integrins in mature 
adipocytes, one study has provided evidence of a potentially important role by 
showing that several integrin signaling components are upregulated in concert 
with ECM factors in adipose tissue from obese human subjects [48].  Also, 
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Farnier et al. showed that the integrin/ERK cascade may be involved in the 
adaptation of cell function to increasing adipocyte size [43].  These findings are 
relevant to the present study as we found that sFRP5 expression was strongly 
correlated with increasing adiposity and adipocyte size.  Additionally, our in vitro 
studies support the existence of a relationship between sFRP5 and integrin/ERK 
signaling, the precedence for which comes from a report by Lee et al. who 
showed direct and functional interaction of sFRP2 with the integrin 
α5β1/fibronectin complex in MCF7 cells [21].  
While independent evidence of a role for the integrin/ERK pathway in 
large adipocytes may lend credence to our findings, it is important to recognize 
the discrepancies between the present study and that of Farnier et al.  For 
example, Farnier and colleagues found that ERK1/2 phosphorylation was 
increased upon activation of integrin β1 signaling in large adipocytes, whereas 
here we report an increase in phosphorylation of ERK1/2 under conditions in 
which we hypothesize integrin activity would be decreased (sFRP5 deficiency).  
These disparities may be due to differences in experimental models as our 
results were obtained using 3T3-L1 cells and primary eMSCs derived from 
C57BL/6J mice and Farnier et al. analyzed adipocytes isolated from Zucker rats.  
Furthermore, ERK1/2 phosphorylation states may be dependent on the particular 
integrin heterodimer initiating the signaling cascade.  Evidence for this comes 
from a recent report showing ERK1/2 phosphorylation is decreased by ~50% 
upon overexpression of integrin α6 in 3T3-L1 adipocytes [40], the same model 
we have used in our studies.   
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Thus, while further research is needed to fully elucidate the role of integrin 
signaling in adipocyte biology, we have provided evidence to suggest that 
integrins may be involved in mediating sFRP5-dependent effects.  Based on 
published reports and data presented here, we hypothesize that ECM-bound 
sFRP5 may interact with integrins at the cell surface and influence downstream 
activation of the integrin/ERK cascade to regulate adipocyte function, including 
adipocyte growth during obesity. 
We have presented evidence of a novel role for sFRP5 in adipocyte 
biology and obesity.  Many question remain, however, that must be addressed to 
gain a full understanding of the mechanism of action of sFRP5.  It has been 
reported that canonical Wnt signaling is downregulated in mature adipocytes, 
raising the questions of what sFRP5 may be acting on and what role sFRP5 
plays at the cell surface?  Future experiments testing the interaction of sFRP5 
with frizzled receptors or integrin molecules expressed in adipocytes will shed 
light on whether sFRP5 plays a direct signaling role leading to altered adipocyte 
function.    
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Figure 2.1.  Expression and Localization of sFRP5 In Vitro and In Vivo.  A, 
RNA was isolated from confluent 3T3-L1 cells (PA) and at the time points 
indicated after induction of differentiation with MDI.  sFRP2 and sFRP5 
transcripts were measured by quantitative RT-PCR (qPCR).  All values for 
sFRP2 and sFRP5 are plotted as percent of maximum.  B, White adipose tissue 
from B6.Cg-Ay/J mice (n=4) was separated into stromal vascular and primary 
adipocyte fractions by collagenase digestion.  sFRP5 mRNA expression was 
determined by qPCR.  Data are expressed as mean plus S.D.  C, 293T cells 
were transiently transfected with pcDNA3.1+ empty vector or vector containing 
an sFRP5-myc fusion construct.  sFRP5 protein is secreted but remains 
associated with the ECM.  Upon addition of exogenous heparin (10 µg/ml), 
sFRP5 is released into the conditioned media.  SV, stromal vascular; AD, 
adipocyte; CL, cell lysate; CM, conditioned media; ECM, extracellular matrix.  
Significance was determined using Student’s t-test.  P-values < 0.05 are depicted 
with an asterisk.  
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Figure 2.2.  sFRP5 is Associated with Increasing Adiposity and Adipocyte 
Size.  A, RNA was isolated from adipose tissue of wild type C57BL/6J mice fed 
either a low fat or a high fat diet for six months.  A strong positive correlation is 
observed between relative expression of sFRP5 mRNA and percent body fat 
(R2=0.8426), whereas sFRP2 mRNA expression and percent body fat do not 
exhibit a positive relationship.  B, sFRP5 expression is also correlated with 
percent body fat in mice that became obese following ovariectomy (R2=0.7579).  
C, Levels of sFRP5 mRNA showed a strong positive correlation with relative 
adipocyte size (R2=0.7884).  Relative adipocyte size was determined by 
comparing the number of adipocytes in a given microscopic field.  Leptin 
(R2=0.5141) and sFRP2 (R2=0.1917) levels are shown for comparison.  D, Wild 
type or LXRβ -/- mice were fed either a low fat or a high fat diet for six months.  
sFRP5 mRNA levels were measured by qPCR.  Data are expressed as mean 
plus S.D.  For all experiments, 6-10 animals per genotype were used.  
Significance was determined using Student’s t-test.  Asterisk denotes 
significance (p < 0.05) between wild type low fat versus wild type high fat. 
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Figure 2.3.  sFRP5Q27stop Mice Resist Diet-Induced Obesity and Display a 
Reduction in Fat Mass.  A, Diagram depicting the full-length sFRP5 protein and 
the predicted protein fragment in sFRP5Q27stop mice.  B, Male wild type (n=15) 
and sFRP5Q27stop (n=14) mice were placed on a high fat diet for five weeks and 
total body weight was measured every week.  Body weight is expressed as mean 
± S.D.  C, Body composition was determined by duel energy X-ray 
absorptiometry scanning in wild type and sFRP5Q27stop mice.  Data are expressed 
as mean plus S.D.  D, Percent body fat was determined by dividing the fat mass 
by the total body weight and expressed as percent plus S.D.  E, Random fed 
plasma leptin and insulin concentrations were detected by ELISA and expressed 
as mean plus S.D.  F, Wild type and sFRP5Q27stop mice were fasted for 12 hours 
and glucose was administered intraperitoneally.  Data are expressed as mean ± 
S.D.  BMC, bone mineral content; CRD, cysteine rich domain; NTR, netrin 
domain.  Significance was determined using Student’s t-test.  P-values < 0.05 are 
depicted with an asterisk. 
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Figure 2.4.  sFRP5 Regulates Adipocyte Size During Obesity in a Tissue 
Autonomous Manner.  A, Male wild type (n=4) and sFRP5Q27stop (n=4) mice 
were fed a high fat diet for six weeks.  G-WAT was excised and weighed.  Data 
are expressed as mean plus S.D.  B, Gonadal adipose tissue was portioned into 
four quadrants for further analysis.  C, Size of adipocytes in quadrants 1-4 were 
determined by MetaMorph analysis and plotted as percentage of large cells (> 
8000 µm2) plus S.D.  D, The average numbers of CLS from quadrants 1-4 are 
presented as mean plus S.D.  E, Gonadal adipose tissue from wild type (n=6) or 
sFRP5Q27stop (n=6) donors was transplanted subcutaneously into db/db (n=3) 
recipients at four weeks of age.  F, Tissue transplants were harvested after ten 
weeks and subjected to morphometric analysis.  Data are expressed as 
percentage of large cells (> 8000 µm2) plus S.D. in donor mice before and after 
transplantation.  G-WAT, gonadal white adipose tissue; CLS, crown-like 
structures.  Significance was determined using Student’s t-test.  P-values < 0.05 
are depicted with an asterisk.  P-values < 0.1 are marked with a cross. 
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Figure 2.5.  Relative Expression of Adipocyte and Vasculature Markers in 
sFRP5Q27stop Mice.  A,B,C, RNA was isolated from gonadal adipose tissue of 
female wild type and sFRP5Q27stop mice that had been challenged with a high fat 
diet.  mRNA expression of the indicated vasculature markers (A), adipocyte 
markers (B), and sFRP transcripts (C) was determined by qPCR.  Data are 
expressed as mean plus S.D.  Significance was determined using Student’s t-
test.  P-values < 0.05 are depicted with an asterisk.  
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Figure 2.6.  Metabolic Phenotype of Mice Harboring the sFRP5Q27stop 
Mutation.  A, Male wild type (n=15) and sFRP5Q27stop (n=10) mice fed a high fat 
diet for 10 weeks were individually housed and food intake was measured every 
2 days for 1 week.  Data are expressed as average food consumed per animal in 
1 week plus SD.  B, Mice were housed as in A and feces was collected at the 
end of 1 week and subjected to fecal fat analysis.  Data are expressed as 
average fat excreted in 1 week plus SD.  C,D,E,F, Male Wild type (n=15) and 
sFRP5Q27stop (n=13) mice were placed in a comprehensive lab animal monitoring 
system (CLAMS) for 3 days.  Data from day 3 are expressed as mean ± SEM for 
(C) oxygen consumption, (D) carbon dioxide production, (E) respiratory quotient, 
and (F) Z-activity.  Significance was determined using Student’s t-test.  P-values 
< 0.05 are depicted with an asterisk. 
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Figure 2.7.  Integrin Signaling may Mediate sFRP5-Regulated Adipocyte 
Clustering.  A, 3T3-L1 preadipocytes were infected with constructs expressing 
sFRP5 or short hairpin RNAs, (1) and (4), against sFRP5 and induced to 
differentiate along with vector controls in the presence of insulin and 
dexamethasone.  Images were taken 12 days post induction.  B, sFRP5 deficient 
3T3-L1 adipocytes were released with EDTA and re-plated onto culture dishes 
coated with collagen type IV.  Images were taken within one hour of re-plating.  
C, 3T3-L1 preadipocytes expressing sFRP5-myc were imbedded in collagen type 
I gels in the presence of integrin β1 blocking antibody or IgM isotype control 
antibody.  Percent contraction of the gels was measured over time as described 
in materials and methods.  Data are expressed as mean plus S.D.  D, sFRP5-
deficient 3T3-L1 cells or eMSCs derived from sFRP5Q27stop mice were induced to 
differentiate as described in materials and methods.  Cells were starved for four 
hours in DPBS then stimulated with 20 or 100 nM insulin for 30 minutes and 
harvested as whole cell lysates.  Activation of factors downstream of integrin 
signaling was measured by western blot.  p-FAK, phospho-focal adhesion 
kinase; p-ERK1/2, phospho-extracellular signal-regulated kinases 1/2;  t-ERK1/2, 
total ERK1/2.  Significance was determined using Student’s t-test.  P-values < 
0.05 are depicted with an asterisk. 
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Figure 2.8.  sFRP5 Regulates Adipocyte Growth and Preadipocyte 
Recruitment.  In this model, expanding adipocytes secrete higher levels of 
sFRP5, which further influences adipocyte growth during obesity.  Additionally, 
sFRP5 may feedback to inhibit autocrine Wnt signaling in preadipocytes, thus 
allowing the recruitment and differentiation of new adipocytes to facilitate 
increased lipid accumulation.  
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Chapter III 
Expanding the Scope of sFRP5 Function 
 
Introduction 
 sFRPs comprise a class of endogenous inhibitors of Wnt signaling that are 
expressed in many tissues throughout development and adulthood [1].  A 
growing literature is now uncovering the functions of many sFRPs in biological 
and pathological processes [2]; however, a specific role for sFRP5 has not been 
as forthcoming.  In the previous chapter we presented data demonstrating a 
novel function for sFRP5 in adipocyte biology and obesity.  In the current chapter 
we describe additional preliminary results suggesting that sFRP5 may directly or 
indirectly regulate the seemingly distinct processes governing food intake under 
specific conditions, bone mass, and local metabolism in adipocytes.   
  Utilizing high fat-challenged sFRP5Q27stop mice we show that food intake, 
while not different under standard room temperature conditions, is decreased 
compared to wild type mice when animals are housed at 27oC, a temperature 
approaching the thermoneutral zone in mice.  This occurs with no detectable 
difference in total body weight between wild type and sFRP5Q27stop mice. 
 Stemming from numerous recent reports suggesting a primary role for Wnt 
signaling in the regulation of bone mass [3-7], we performed microcomputerized 
tomography (µCT) analysis on femurs from wild type and sFRP5Q27stop mice.  
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Interestingly, our analysis revealed a decrease in cortical bone mineral density 
and content in mice lacking functional sFRP5. 
 To gain a global perspective of genes or pathways that may be regulated 
by sFRP5, we performed a microarray analysis on RNA isolated from G-WAT of 
high fat-fed wild type and sFRP5Q27stop mice.  Results from this experiment 
suggest that there may be an upregulation of genes involved in mitochondrial 
oxidative phosphorylation in sFRP5Q27stop mice, hinting at possible alterations of 
adipocyte metabolism in these animals. 
 Thus, in the current chapter we describe various pieces of data that may 
expand the scope of sFRP5 function and provide additional insight into the 
overall impact of this factor on vertebrate biology. 
 
Materials and Methods 
Animals 
 Animal care was overseen by the Unit for Laboratory Animal Medicine 
(University of Michigan).  sFRP5Q27stop mice were generated by ENU 
mutagenesis in which a C79T mutation created a premature stop codon at Gln 
27, likely producing a null allele [8].  All animals were individually housed as 
indicated at room temperature or in a controlled temperature room set at 27oC 
with a regular 12-hour light/dark cycle and were fed ad libitum with a high fat diet 
(4.73 kcal/g, 45% fat, D12451, Research Diets) for 12-18 weeks. 
 
Fasted Blood Glucose and Serum Insulin 
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 Mice were fasted for 12 hours prior to experimentation.  Blood glucose 
was measured in wild type and sFRP5Q27stop tail blood with the OneTouch 
UltraTM glucometer (Lifescan, Burnaby, British Columbia, Canada).  Serum 
insulin was determined using an enzyme-linked immunosorbent assay kit (Crystal 
Chem, Downers Grove, IL) according to the manufacturer’s instructions. 
 
Microcomputerized Tomography (µCT) 
 µCT was used to analyze femurs from hindlimbs of female wild type and 
sFRP5Q27stop mice challenged with a high fat diet as described [9] by using the 
Stereology function of GE Medical Systems MICROVIEW software. 
 
Microarray Analysis 
 RNA was isolated from G-WAT of male wild type and sFRP5Q27stop mice.  
cDNA was amplified and purified using the WT Pico assay (NuGen Inc.) following 
the manufacturer’s standard protocol.  Four micrograms of cDNA was converted 
to sense orientation using the Exon Module (NuGen Inc.) and subsequently 
fragmented and biotinylated using the Ovation FL Module (NuGen Inc.) following 
the manufacturers standard protocol.  The probe was then hybridized to 
Affymetrix Mouse Gene ST 1.0 GeneChips for 20 hours at 45oC, stained, and 
washed using a Fluidics FS450 instrument, and then scanned with the Affymetrix 
7G Scanner 3000.  Data were analyzed using Ingenuity Pathway Analysis 
software (Ingenuity Systems, Redwood City, CA) to identify relevant biological 
networks. 
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Results 
Temperature Dependent Effects on Food Intake in sFRP5Q27stop Mice 
 To define further the conditions of obesity resistance in sFRP5Q27stop mice, 
we challenged both male and female wild type and sFRP5Q27stop mice at four 
weeks of age with a high fat diet, measuring total body weight and food intake at 
regular intervals over a 12-week period.  Mice were individually housed at room 
temperature (25oC) for the first six weeks (weeks 1-6) and at 27oC for the last six 
weeks (weeks 7-12).  This design allowed us to test whether environmental 
factors play a role in obesity resistance in this model, and whether slight 
differences in food intake over time may contribute to decreases in body weight 
and fat mass in male or female sFRP5Q27stop mice.  Somewhat unexpectedly 
based on our previous data, no differences in total body weight were observed 
between male or female wild type and sFRP5Q27stop mice over the 12-week 
period (Figure 3.1a, and data not shown).  Despite this observation, food intake 
was decreased in female sFRP5Q27stop mice housed at 27oC (weeks 7-12), while 
there was no change in food intake when these mice were housed at room 
temperature (weeks 1-6) (figure 3.1b).   
 The finding that food intake was altered without concomitant changes in 
body weight led us to question whether there were differences in body 
composition that were not reflected in the total body weight.  However, our 
analysis of G-WAT and dorsolumbar white adipose tissue (D-WAT) revealed no 
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difference in the weight of these adipose depots between wild type and 
sFRP5Q27stop mice (Figure 3.1c).  
 To determine whether insulin or glucose homeostasis was affected under 
these conditions, wild type and sFRP5Q27stop mice were fasted for 12 hours at the 
conclusion of the experiment (week 12) and analyzed for blood glucose and 
serum insulin levels.  Our results indicate that there are no differences in fasted 
blood glucose or fasted serum insulin in high fat-fed wild type and sFRP5Q27stop 
mice housed at 27oC (Figure 3.1d).  
 Taken together, our results suggest that under certain environmental 
conditions, food intake is decreased in sFRP5Q27stop mice compared to controls, 
and that this occurs without an attendant decrease in total body weight or 
alteration of glucose and insulin homeostasis. 
 
µCT Analysis of Cortical and Trabecular Bone in sFRP5Q27stop Mice 
 Numerous recent reports have confirmed that several Wnt pathway 
members, including sFRPs, play a central role in the regulation of bone mass in 
mammals [3-7].  As deletion of sFRP1 leads to increased trabecular bone 
formation [5] and targeted overexpression of sFRP4 promotes a low bone mass 
phenotype [6], we sought to characterize the effect of sFRP5 on bone mass in 
sFRP5Q27stop mice.  Wild type and sFRP5Q27stop mice were challenged with a high 
fat diet for 18 weeks, following which femurs were collected and submitted for 
µCT analysis of cortical and trabecular bone.  Our results suggest that bone 
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mineral density (BMD), bone mineral content (BMC), and the outer perimeter of 
cortical bone are decreased in sFRP5Q27stop femurs (Figure 3.2a,b,c). 
 Since Wnt signaling has been shown to play a particularly important role in 
trabecular bone formation, we hypothesized that sFRP5 may affect this process.  
However, µCT analysis of trabecular bone formation in sFRP5Q27stop mice 
revealed no difference in BMD, BMC, or bone volume fraction (Figure 3.2d,e,f) in 
femurs from sFRP5Q27stop mice compared to wild type controls. 
 Investigation of mRNA isolated by flushing the marrow cavity of C57BL/6J 
femurs suggests that sFRP5 is not expressed in bone marrow (data not shown).  
Thus, while our data suggest that sFRP5 regulates cortical bone formation, it is 
possible that this may be an indirect effect. 
 
Microarray Analysis of G-WAT from sFRP5Q27stop mice  
 To obtain a global perspective of genes or cellular pathways that may be 
regulated by sFRP5, we performed a microarray analysis on G-WAT from male 
high-fat-challenged wild type and sFRP5Q27stop mice.  This cohort was the male 
counterpart to the female cohort described in figure 3.1.  As described above, the 
mice were challenged with a high fat diet at four weeks of age for 12 weeks.  Like 
the female cohort reported in figure 3.1, male mice did not exhibit a difference in 
total body weight (data not shown).  In contrast to findings with female mice, 
however, male wild type and sFRP5Q27stop mice did not show a difference in food 
intake (data not shown).  Therefore, this cohort was selected for subsequent 
microarray analysis based on the above observations, enabling us to evaluate 
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changes in gene expression resulting from loss of sFRP5 and not general 
differences associated with altered body weight or food intake. 
 Microarray data were analyzed using Ingenuity Pathway Analysis (IPA) 
software to identify relevant biological networks or pathways that may be altered 
in sFRP5Q27stop mice compared to wild type controls.  Approximately 3,000 probe 
sets were populated into the IPA program and about 850 were eligible for 
network/pathways analysis.  Table 3.1 shows the top 10 pathways identified by 
IPA of differentially expressed genes.  The pathways identified as Oxidative 
Phosphorylation and Mitochondrial Dysfunction are highly regulated and contain 
a number of genes involved in oxidative phosphorylation that are statistically 
upregulated in adipose tissue from sFRP5Q27stop mice (Table 3.1).   
 Networks generated from IPA reveal an upregulation of cytochrome c 
oxidase subunits Cox7b, Cox17, Cox6b1, Cox6a1, Cox6c, Cox5b, Cox2, and 
Cox7c (Figure 3.3).  Interestingly, our microarray data also indicate that the 
Huntingtin protein (HTT) is downregulated in sFRP5Q27stop adipose tissue.  HTT 
has been suggested to regulate cellular energetics, in part through alterations in 
the activity of complex II in the electron transport chain [10].  In addition to 
cytochrome c oxidase (complex IV) subunits, ATP synthase subunits Atp6vd1, 
Atp5l, Atp5g2, Atp5h, Atp6v1g1, and Atp6v1g2 are increased in sFRP5Q27stop 
adipose tissue, as are NADH2 dehydrogenase subcomplexes, Ndufb5, Ndufa1, 
Ndufa13, Ndufa6, Ndufb6, and Ndufs6 (Figure 3.4).  Moreover, Gene Ontology 
(GO) analysis found that oxidative phosphorylation was one of the biological 
processes over-represented in adipose tissue from sFRP5Q27stop mice (data not 
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shown).  Thus, the results of our microarray analyses support the hypothesis that 
oxidative phosphorylation is increased in adipocytes of sFRP5Q27stop mice. 
 
Discussion 
 Here we provide evidence that sFRP5 may influence food intake under 
certain conditions.  Our data also suggest that sFRP5 regulates cortical bone 
mass and possibly oxidative phosphorylation in adipocytes.  While these effects 
are somewhat diverse with regard to mechanism, the results serve to highlight a 
broader scope for sFRP5 function in vertebrate biology.   
 The finding that food intake is decreased in sFRP5Q27stop mice is 
interesting as this effect was only observed once the mice were housed at 27oC.  
This implies that there may be interactions between sFRP5 function and 
environmental factors, such as temperature.  Alternatively, it could be argued that 
food intake appeared to be decreasing in sFRP5Q27stop mice prior to the animals 
being housed at 27oC, and that if left at room temperature, the differences may 
have reached statistical significance.  In any case, it is tempting to extrapolate 
the data and speculate that decreases in food intake over time are the cause of 
obesity resistance in sFRP5Q27stop mice (Figure 2.3).  However, it is important to 
remember that we observed a decrease in fat mass and total body weight in 
sFRP5Q27stop mice under entirely different experimental conditions than those 
outlined in the current chapter.  For example, in the experiments performed 
previously, wild type and sFRP5Q27stop mice were placed on a high fat diet 
beginning at 12-16 weeks of age, while the cohort described in the current 
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chapter began receiving the same diet at four weeks of age.  Also, the mice 
described here were housed at two different temperatures, while the mice 
described in chapter II were kept at a constant temperature (room temperature) 
throughout the entire experiment.  Furthermore, our previous data from the 
adipose tissue transplantation implies that differences in adipocyte growth during 
obesity are not dependent on food intake.  Therefore, pending further 
experimentation, we cannot conclude that the previously reported decrease in fat 
mass and body weight observed in sFRP5Q27stop mice is a result of decreased 
food intake. 
 Additionally, while our finding that fasted plasma insulin is similar in wild 
type and sFRP5Q27stop mice may seem at odds with previous observations in 
chapter II, it should be noted that insulin was measured here during a fasted 
state, while the previous data was obtained during the fed state.  Nonetheless, 
the fact that fasted insulin levels are similar in the same cohort that show no 
statistical difference in body weight suggests that the differences in fed insulin 
levels observed in chapter II may simply be a reflection of altered adiposity in 
sFRP5Q27stop mice, and not a direct effect on insulin secretion per se. 
 As Wnt signaling has recently been shown to regulate multiple aspects of 
bone biology, we sought to determine whether sFRP5Q27stop mice exhibit a bone 
phenotype.  Here we show that cortical bone parameters, BMD, BMC, and outer 
perimeter, are all decreased in sFRP5Q27stop mice as measured by µCT.  This 
was somewhat unexpected based on the established role of Wnt signaling in 
bone formation.  We reasoned that if sFRP5 were acting as a classical Wnt 
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inhibitor in this context, then we would expect to observe an increase in bone 
formation in sFRP5Q27stop mice, where presumably Wnt activity is high.  However, 
we observed the opposite result in cortical bone and no effect on trabecular 
bone.  Our attempts to quantify sFRP5 mRNA expression in bone marrow led us 
to conclude that sFRP5 is not expressed, or is expressed at very low levels, in 
that tissue.  Therefore, we speculate that the effect seen in cortical bone of 
sFRP5Q27stop mice is likely an indirect effect, possibly due to the altered adiposity 
we observed previously.  
 Our attempt to identify genes or pathways altered in sFRP5Q27stop mice led 
to the finding that oxidative phosphorylation may be increased in these animals.  
Microarray analysis revealed an increase in expression of genes whose products 
comprise many of the proteins involved in complexes I, IV, and V of the electron 
transport chain.  Specifically, subunits of cytochrome c oxidase, NADH2 
dehydrogenase, and ATP synthase were all upregulated in sFRP5Q27stop adipose 
tissue compared to controls. 
 In light of previous observations that sFRP5Q27stop mice exhibit a smaller 
proportion of large adipocytes in the obese state, the finding that oxidative 
phosphorylation may be increased in sFRP5Q27stop mice supports a hypothesis 
wherein increased oxidation of fatty acids may underlie differences in adipocyte 
size.  Although no differences were observed in whole body oxygen consumption 
of sFRP5Q27stop mice (Figure 2.6c), undetected changes in local adipocyte 
metabolism may contribute to small but significant differences in adipocyte 
volume over time.   
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 To test this hypothesis, mitochondrial size and number should be 
evaluated in wild type and sFRP5Q27stop adipocytes to determine whether 
mitochondrial biogenesis is altered.  Furthermore, β-oxidation and oxygen 
consumption should be measured in adipocytes from sFRP5Q27stop mice to 
investigate possible alterations in local metabolism that may underlie the 
observations previously reported (Figure 2.3, 2.4). 
 Here we have provided additional preliminary data suggesting a role for 
sFRP5 in the regulation of bone mass, adipocyte metabolism, and food intake 
under certain conditions.  Though seemingly unrelated, these effects are not 
entirely unexpected as sFRP5 function is disrupted in all tissues of sFRP5Q27stop 
mice.  Thus, our data strengthen the notion that sFRP5 plays diverse roles in 
regulating multiple aspects of vertebrate biology during obesity.
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Figure 3.1.  Temperature Dependent Effects on Food Intake in sFRP5Q27stop 
Mice.  A, Four week old female wild type (n=8) and sFRP5Q27stop (n=10) mice 
were challenged with a high fat diet for 12 weeks while housed at either room 
temperature (weeks 1-6) or at 27oC (weeks 7-12).  Total body weight was 
measured every week.  Data are expressed as mean ± S.D. B, Food intake was 
measured once (weeks 1-6) or twice (weeks 7-12) a week for 12 weeks.  Data 
are expressed as mean food intake per week ± S.D.  C, G-WAT and D-WAT 
were excised and weighed.  Data are expressed as mean plus S.D.  D, Fasted 
blood glucose and serum insulin were measured at the end of the 12-week 
period.  Data are expressed as mean plus S.D.  HFD, high fat diet.  G-WAT, 
gonadal white adipose tissue; D-WAT, dorsolumbar white adipose tissue.  
Significance was determined using Student’s t-test.  P-values < 0.05 are depicted 
with an asterisk.
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Figure 3.2.  µCT Analysis of Cortical and Trabecular Bone in sFRP5Q27stop 
Mice.  A,B,C, µCT analysis conducted on cortical bone from femurs of female 
wild type (n=5) and sFRP5Q27stop (n=6) mice measured (A) outer perimeter, (B) 
BMD, and (C) BMC.  D,E,F, µCT analysis conducted on trabecular bone from the 
same femurs measured (D) volume, (E) BMD, and (F) BMC.  Data are expressed 
as mean plus S.D.  µCT, microcomputerized tomography; BMD, bone mineral 
density; BMC, bone mineral content.  Significance was determined using 
Student’s t-test.  P-values < 0.05 are depicted with an asterisk. 
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Figure 3.3.  Ingenuity Pathway Analysis of Cytochrome C Oxidase Subunit 
Upregulation in sFRP5Q27stop mice.  Ingenuity pathway analysis of networks 
altered in sFRP5Q27stop mice revealed an upregulation of cytochrome c oxidase 
subunits, seen on the right-hand side of the figure.  An upregulation in 
complement factors is seen at the bottom of the figure.  Red indicates genes that 
are upregulated; green indicates genes that are downregulated. 
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Figure 3.4.  Ingenuity Pathway Analysis of NADH2 Dehydrogenase and ATP 
synthase Subunit Upregulation in sFRP5Q27stop Mice.  Ingenuity pathway 
analysis of networks altered in sFRP5Q27stop mice revealed an upregulation of 
NADH2 subunits and ATP synthase subunits, seen on the upper right-hand side 
and lower right-hand side of the figure, respectively.  Red indicates genes that 
are upregulated; green indicates genes that are downregulated. 
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Table 3.1.   Top 10 Pathways Identified by IPA of Differentially Expressed 
Genes.  Pathway analysis of differentially expressed genes identified by 
microarray analysis of adipose tissue from wild type and sFRP5Q27stop mice.  The 
pathways identified as Oxidative Phosphorylation and Mitochondrial Dysfunction 
are highly related and contain a number of statistically upregulated genes 
involved in oxidative phosphorylation. 
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Summary of Results 
  Research conducted over the past decade has established the Wnt/β-
catenin signaling pathway as a primary regulator of adipocyte differentiation [1-4].  
Animal and human studies have extended prior in vitro observations and 
highlighted significant additional roles for Wnt/β-catenin signaling in disease 
processes such as obesity and type 2 diabetes [5-7].  Further complexity in the 
pathway arises from the regulated expression of endogenous inhibitors of Wnt 
signaling, including the family of secreted frizzled-related proteins (sFRPs).  
Numerous reports have shown that sFRPs inhibit Wnt signaling in vitro and in 
vivo by competitively binding Wnt ligands or frizzled receptors and blocking 
downstream activation of the pathway [8-11].  However, recent studies have 
confirmed additional roles for sFRPs that are independent of their classical Wnt-
inhibitory function [12]. 
 Here we report the finding that sFRP5 expression is dramatically induced 
during adipocyte differentiation of 3T3-L1 cells in culture (Figure 2.1a).  Analysis 
of adipocytes and stromal vascular cells from adipose tissue yielded results 
consistent with those previously reported by Koza et al. [13], who showed that 
sFRP5 is expressed predominantly in the adipocyte fraction (Figure 2.1b).  Koza 
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et al. also found that sFRP5 expression is correlated with increasing weight gain 
[13].  Here we extend those findings to show that sFRP5 expression is highly 
correlated with increasing adiposity and relative adipocyte size in multiple models 
of diet-induced and genetic obesity (Figure 2.2).  Further evidence in support of 
an association between sFRP5 and adipocyte size comes from our studies using 
LXRβ -/- mice, the adipocytes from which do not undergo diet-induced 
hypertrophy.  We found that while sFRP5 expression is increased 25 fold in high 
fat-fed wild type mice compared to low fat fed-controls, levels of sFRP5 mRNA 
are not different in LXRβ -/- mice under the same conditions (Figure 2.2d).  
Together, these results point to a strong correlation between sFRP5 expression 
and adipocyte expansion during obesity.  
 As sFRP5 expression in adipose tissue is elevated in every model of 
obesity analyzed, we sought to characterize the role of sFRP5 using genetically 
modified, loss-of-function mice.  Here we show that sFRP5Q27stop mice resist diet-
induced obesity as evidenced by a decrease in total body weight and a reduction 
in fat mass, with no differences observed in the weight of other tissues (Figure 
2.3, and data not shown).  Investigation of circulating factors suggests that both 
fed insulin and leptin are decreased in sFRP5Q27stop mice, possibly secondary to 
the decrease in fat mass observed by DEXA (Figure 2.3e). 
 A detailed examination of adipose tissue from wild type and sFRP5Q27stop 
mice revealed that loss of sFRP5 limits the creation of large (> 8000 µm2) 
adipocytes (Figure 2.4c).  As sFRP5Q27stop mice resist diet-induced weight gain, 
we questioned whether the observed effect on adipocyte size was a tissue 
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autonomous effect or simply a result of decreased adiposity in these animals.  To 
address this question, we performed an adipose tissue transplant experiment 
wherein portions of gonadal white adipose tissue (G-WAT) from wild type and 
sFRP5Q27stop donors were transplanted into db/db recipients to rapidly drive 
adipocyte hypertrophy of the donor tissue (Figure 2.4e).  In agreement with our 
previous finding, analysis of donor G-WAT before and after transplantation 
showed that sFRP5Q27stop adipose tissue contains proportionally fewer large 
adipocytes compared to controls (Figure 2.4f). 
 To identify the underlying cause limiting the creation of large adipocytes in 
sFRP5Q27stop mice, we analyzed mRNA expression of factors known to play a role 
in vascular formation and recruitment of new vessels during obesity.  However, 
our results indicate that vascular markers Ang-1, Ang-2, Tie-1, Tie-2, and ACTA2 
are not altered in sFRP5Q27stop G-WAT compared to controls (Figure 2.5a). 
 We also investigated the metabolic profile of sFRP5Q27stop mice using a 
comprehensive lab animal monitoring system (CLAMS) to measure oxygen 
consumption, carbon dioxide production, respiratory quotient, and activity.  The 
results of these studies suggest that in general, whole body metabolism of 
sFRP5Q27stop mice is similar to that of wild type controls, with the unanticipated 
exception that carbon dioxide production appears to be decreased in 
sFRP5Q27stop mice (Figure 2.6). 
 To further elucidate the role of sFRP5 in adipocyte biology, we utilized 
both immortalized and primary cell culture models of adipogenesis.  Here we 
show that 3T3-L1 adipocytes overexpressing sFRP5 form larger and more 
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numerous adipocyte clusters than control cells, whereas sFRP5-depleted 3T3-L1 
cells exhibit very little adipocyte clustering (Figure 2.7a). To extend this finding, 
we performed an adipocyte aggregation experiment in which 3T3-L1 adipocytes 
expressing either a scrambled control or two shRNA molecules against sFRP5 
were detached from the culture dish and re-plated on various ECM substrates.  
Our data suggest that control adipocytes readily form large aggregates upon re-
plating, while sFRP5-deficient adipocytes completely fail to form aggregates, and 
instead adhere to the substratum as mostly single cells (Figure 2.7b).     
 In light of the recent finding that integrins regulate clustering of 3T3-L1 
adipocytes, we sought to determine whether the sFRP5 and integrin pathways 
interact utilizing a model of 3D collagen gel contraction, which has been shown to 
be dependent on integrin function.  Interestingly, our results show that sFRP5-
overexpressing preadipocytes contract collagen gels at an increased rate 
compared to controls, and that this effect is dependent on functional integrin β1 
(Figure 2.7c).  Furthermore, we also show that phosphorylation states of focal 
adhesion kinase (FAK) and extracellular signal-regulated kinases 1/2 (ERK1/2), 
two downstream components of integrin signaling, are altered in sFRP5-deficient 
3T3-L1 adipocytes and in primary ear mesenchymal stem cells (eMSCs) derived 
from sFRP5Q27stop mice (Figure 2.7d). 
 Finally, we present data suggesting that loss of sFRP5 may lead to 
changes in cortical bone mass, local adipocyte metabolism, and temperature-
dependent alterations in food intake (Figure 3.1, 3.2, and 3.3). 
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 In summary, we have provided evidence that sFRP5 regulates adipocyte 
growth during obesity in a tissue autonomous manner, and that this effect may 
be mediated by integrin signaling.  Though our results speak to a novel function 
for sFRP5 in adipocyte biology and obesity, many questions remain unanswered.  
In this chapter we outline some of these questions and discuss possible 
mechanisms by which sFRP5 may affect adipocyte function in light of our current 
understanding. 
 
What Regulates sFRP5 Expression in Adipogenesis and Obesity? 
 Here we show that sFRP5 expression is increased substantially during 
adipocyte differentiation and in various models of obesity, displaying a strong 
positive correlation with percent body fat and relative adipocyte size (Figure 2.1, 
2.2).  However, the factors regulating sFRP5 expression under these 
circumstances remain unknown.  While one published report indicates that the 
LIM-homeodomain transcription factor Lhx5 increases expression of sFRP5 in 
the forebrain [14], no studies have yet been published regarding regulation of 
sFRP5 in adipose tissue. 
 Perhaps more than any other cell type, adipocytes undergo dramatic 
changes in cell size under physiological conditions.  Based on our previous 
results from the adipose tissue transplant described in chapter II, sFRP5 appears 
to be involved in controlling adipocyte hypertrophy during obesity (Figure 2.4f).  
However, this does not discount the possibility that sFRP5 expression may 
originally be upregulated by the initiation of hypertrophy in these cells.  Support 
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for this hypothesis comes from our analysis of sFRP5 expression in high fat-fed 
LXRβ -/- mice where we observed no increase in sFRP5 expression in the 
absence of diet-induced adipocyte hypertrophy (Figure 2.2d).  It is possible that 
as cell volume begins to increase under a growing lipid load, sFRP5 may be 
upregulated by increases in receptor signaling from the expanding cell 
membrane.  Though speculative at this stage, recent evidence suggests that 
changes in cell volume may act as signals for basic cellular functions [15] and 
that cell volume changes may activate plasma membrane receptors including 
tyrosine kinase receptors, G-protein coupled receptors, and integrins, which are 
also known to participate in the regulation of cell size [16].  Thus, sFRP5 may be 
upregulated by increased activity of signaling pathways in expanding adipocytes, 
and in turn function to further influence adipocyte growth under conditions of 
obesity. 
 Another possibility involves an indirect mechanism for increasing sFRP5 
expression in large adipocytes.  It is well established that insulin sensitivity is 
inversely correlated with adipocyte size [17,18].  Thus, as adipocyte volume 
increases to facilitate lipid storage, sFRP5 upregulation may occur secondary to 
the development of insulin resistance in these cells.  Future experiments to test 
this hypothesis should analyze sFRP5 expression in adipocytes from AMPKα2 -/- 
mice, or a similar model which exhibit an increase in adipocyte size without 
attendant insulin resistance [19].  
 
Which Signaling Pathways Mediate sFRP5-Dependent Effects? 
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 Classical models of sFRP function suggest that these factors bind to and 
sequester Wnt ligands in the extracellular space, blocking interaction with 
Frizzled receptors and preventing downstream activation of the pathway.  To 
date, there have been no published reports of endogenous Wnt ligands 
expressed in mature adipocytes, which if true suggests that sFRP5 does not 
function by binding Wnts secreted by adipocytes.  Recent reports, however, have 
provided evidence for additional mechanisms whereby sFRPs influence cellular 
processes.  Studies proposing direct activation of Frizzled receptors by sFRPs 
independent of Wnt ligands are particularly interesting [20,21] and provide a 
premise for hypothesizing that sFRP5 may affect adipocyte function by directly 
signaling through frizzled receptors.  Although Wnt/β-catenin signaling is 
suppressed during adipogenesis [4], the possibility exists that non-canonical or 
other signaling may be initiated through sFRP5/Frizzled interactions.  To test this 
hypothesis, expression patterns of Frizzled receptors should be evaluated in 
adipocytes to rule out those that are not expressed.  Frizzled receptors displaying 
appropriate expression patterns could then be evaluated for biochemical and 
genetic interaction with sFRP5 in cell culture and animal models. 
 sFRPs contain two main domains, a cysteine-rich domain (CRD) 
homologous to the CRD in Frizzled receptors, and a Netrin domain (NTR) 
homologous to a domain of the same name in Netrin molecules, which have well-
established roles in axonal guidance [22].  Little has been published with regard 
to the function of the NTR domain in sFRPs, although there are intriguing 
parallels between our observations of sFRP5 function and those reported for 
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Netrin-1.  For example, Netrin-1 affects axon attraction and outgrowth through 
activation of FAK [23-25] and we observed a decrease in FAK phosphorylation in 
two models of sFRP5-deficient adipocytes (Figure 2.7d).  Additionally, activation 
of retinal neurons by Netrin-1 has been shown to stimulate protein synthesis and 
degradation through the ERK1/2 and ubiquitin pathways, respectively [26,27].  
Similarly, we found that sFRP5 influences ERK1/2 phosphorylation in adipocytes 
(Figure 2.7d) and that several factors involved in the ubiquitination pathway are 
significantly altered in our microarray analysis of adipose tissue from 
sFRP5Q27stop mice (Table 3.1).  Furthermore, the fact that Netrin-1 interacts with 
its receptor via the netrin domain [28], a domain shared by sFRP5, leads to the 
speculation that sFRP5 may interact with and signal through netrin receptors in 
adipocytes.  To test this hypothesis, functional studies involving deletion of the 
NTR domain in sFRP5 should be performed, in addition to assays examining a 
biochemical interaction between sFRP5 and Netrin receptors.     
 In addition to interaction with Frizzled or Netrin receptors, our finding that 
the integrin/ERK pathway is altered in cells lacking functional sFRP5 supports an 
additional model in which sFRP5 interaction with integrins at the cell surface 
influences adipocyte function through activation of integrin signaling.  Previously, 
it was reported that sFRP2 can influence cell adhesion and apoptosis through 
interaction with fibronectin and integrin α5β1 in MCF7 cells [29].  Furthermore, it 
has been shown that integrin α6 is induced during adipocyte differentiation and 
regulates adipocyte clustering [30], two findings that parallel our observations 
with sFRP5 in 3T3-L1 cells (Figure 2.1a, 2.7a).  Also, our data support a 
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functional interaction between sFRP5 and integrin β1 in the contraction of 3D 
collagen gels (Figure 2.7c).  Taken together, our results suggest that sFRP5 may 
exert effects on adipocyte biology at least in part through interactions with the 
integrin cascade.  While we show that activation states of ERK1/2 and FAK are 
altered in sFRP5-deficient adipocytes (Figure 2.7d), further evidence of a direct 
interaction with the integrin pathway is needed to confirm this hypothesis.  Co-
immunoprecipitation of candidate integrins, such as integrins α6 or β1, with 
sFRP5 should be performed to test whether these factors physically interact.  In 
this regard, it is interesting to note that Netrin-1 has been shown to influence cell 
adhesion through direct interaction with integrin α6β4 via its NTR domain [31], 
the domain shared with sFRP5.  Moreover, inhibiting the function of integrins in 
adipocytes with commercially available blocking antibodies would test whether 
sFRP5-mediated effects are dependent on integrin function in this context.  
  Thus, further attempts to elucidate the mechanism by which sFRP5 
affects adipocyte function should investigate non-classical roles of sFRPs, 
including the interaction of sFRP5 with the cell surface receptors and pathways 
described above.   
 
Which Cell Types are Targeted by sFRP5? 
 While our data suggest that sFRP5 acts in an autocrine/paracrine manner 
to influence adipocyte function, it is possible that sFRP5 may also signal to other 
cell types in the surrounding microenvironment.  Under these circumstances, 
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rather than functioning as a signaling molecule, sFRP5 may act as an 
extracellular factor capable of performing diverse functions. 
 For example, in the context of obesity where neovascularization of 
adipose tissue is required to meet the energy needs of expanding adipocytes, an 
increased concentration of ECM-bound sFRP5 surrounding large adipocytes may 
serve as a guidance cue to recruit new microvessels to the cells in greatest need 
of nutrients.  Likewise, as cells expand and approach maximum lipid-storing 
capacity, high levels of sFRP5 may act to recruit macrophages to those cells for 
breakdown and disposal.  This hypothesis is supported by the finding that there 
are fewer crown-like structures (CLS) in adipose tissue from sFRP5Q27stop mice 
compared to wild type controls (Figure 2.4d), though this observation may simply 
be secondary to differences in the obesity dependent inflammatory state of these 
animals.  Both hypotheses presented above should be tested with migration 
assays utilizing sFRP5-producing cells as the source.    
  In addition to macrophages and vascular cells, adipose tissue contains 
resident adipocyte precursors, termed preadipocytes, which can be mobilized as 
needed to increase the number of lipid-storing adipocytes within the tissue.  As 
Wnt signaling has been shown to act in an autocrine manner to maintain 
preadipocytes in an undifferentiated state [1], a model emerges in which sFRP5 
is secreted at high concentrations from large adipocytes and feeds back to inhibit 
Wnt ligands secreted by preadipocytes, thus allowing these cells to differentiate 
and facilitate increased lipid accumulation during obesity (Figure 2.8).  Although 
this hypothesis seems reasonable, our data indicate that overexpression of 
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sFRP5 in 3T3-L1 preadipocytes does not result in spontaneous adipogenesis 
(data not shown), suggesting that sFRP5 does not inhibit endogenous Wnts 
expressed by these cells.  However, it is entirely possible that enforcing ectopic 
expression of sFRP5 in preadipocytes is not an accurate representation of 
paracrine signaling between adipocytes and preadipocytes in adipose tissue.  
Furthermore, preadipocytes may not contain the necessary processing 
machinery to correctly fold, package, or secrete an adipocyte protein such as 
sFRP5.  Thus, until purified recombinant sFRP5 protein becomes available for 
use, we cannot conclude that sFRP5 does not function to block Wnt signaling in 
preadipocytes. 
 In summary, though our data support a novel, autocrine/paracrine role for 
sFRP5 in adipocyte biology, it is clear that further research will be needed to 
determine the effects of sFRP5 on all components of adipose tissue during 
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